

(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. **AU 2011229918 B2**

(54) Title
Methods for conducting genetic analysis using protein polymorphisms

(51) International Patent Classification(s)
C12Q 1/68 (2006.01)

(21) Application No: **2011229918** (22) Date of Filing: **2011.03.24**

(87) WIPO No: **WO11/119235**

(30) Priority Data

(31) Number	(32) Date	(33) Country
61/340,918	2010.03.24	US
13/071,249	2011.03.24	US

(43) Publication Date: **2011.09.29**

(44) Accepted Journal Date: **2015.02.05**

(71) Applicant(s)
Parker Proteomics, LLC

(72) Inventor(s)
Parker, Glendon John

(74) Agent / Attorney
Davies Collison Cave, Level 14 255 Elizabeth Street, Sydney, NSW, 2000

(56) Related Art
WO 2000/063683

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
29 September 2011 (29.09.2011)

(10) International Publication Number
WO 2011/119235 A1

- (51) International Patent Classification:
C12Q 1/68 (2006.01)
- (21) International Application Number:
PCT/US2011/000550
- (22) International Filing Date:
24 March 2011 (24.03.2011)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
61/340,918 24 March 2010 (24.03.2010) US
13/071,249 24 March 2011 (24.03.2011) US
- (72) Inventor; and
- (71) Applicant : PARKER, Glendon, John [US/US]; 1033
East 2nd Avenue, Salt Lake City, UT 84103 (US).
- (74) Agents: CROCKETT, Bretton, L. et al.; Morris
O'Bryant Compagni, P.C., 734 East 200 South, Salt Lake
City, UT 84102 (US).

CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PF, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

- Published:
- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,

(54) Title: METHODS FOR CONDUCTING GENETIC ANALYSIS USING PROTEIN POLYMORPHISM

	peptide	mass	allelic frequency
Desmoglein	NTNIAQK SEQ ID NO: 125	787.418	0.78
	I305F NTNFAQK SEQ ID NO: 126	821.403	0.22
	VQYDLQK SEQ ID NO: 127	892.465	0.79
	Y1512C VQCCLQK SEQ ID NO: 128	832.411	0.21
Keratin, type II cuticular Hb2	PCVNEFVALK SEQ ID NO: 129	1247.622	0.99
	E219Q PCVQNEFVALK SEQ ID NO: 130	1246.637	0.01
	GAFLYEPCGVSTPVLSTGVLR SEQ ID NO: 131	2165.119	0.04
	E452D GAFLYIDPCGVSTPVLSTGVLR SEQ ID NO: 132	2151.103	0.68
	M458T GAFLYIDPCGVSMPLVSTGVLR SEQ ID NO: 133	2181.096	0.27
Keratin, type I cuticular Ha2	MVVNIDNAK SEQ ID NO: 74	1002.516	0.93
	I171T MVVNTDNAK SEQ ID NO: 75	990.48	0.05
	S222Y ADLEAQVESLK SEQ ID NO: 134	1201.619	0.46
	ADLEAQVEYLK SEQ ID NO: 135	1277.65	0.54
	T339M DSLENTLYESEAR SEQ ID NO: 58	1463.673	0.99
	DSLENMLTESEAR SEQ ID NO: 59	1493.666	0.01
	T395M IFGGIINTYR SEQ ID NO: 3	1093.54	0.63
	LEGEINMYR SEQ ID NO: 4	1123.533	0.37
	T427P LPCNPGSTPSCITTCVPSPCVTR SEQ ID NO: 136	2264.972	0.19
	LPCNPGSTPSCITTCVPSPCVPR SEQ ID NO: 137	2260.977	0.78
R428C LPCNPGSTPSCITTCVPSPCVTR SEQ ID NO: 136	2264.972	0.79	
LPCNPGSTPSCITTCVPSPCVTCVCPVPR SEQ ID NO: 138	2867.227	0.05	

(57) Abstract: Methods and processes for conducting genetic analysis through protein polymorphisms, including identification of individuals, establishment of paternity and measurement of genetic diversity and distance. Some illustrative embodiments of methods of the present invention include the identification of peptide biomarkers using proteomic techniques, including liquid chromatography-tandem mass spectrometry from biological samples, using hair, dentin, or bone as a source of the protein to be analyzed. Other illustrative embodiments include the determination of allelic frequency and feasibility of protein polymorphism peptide biomarkers, and the application of these frequencies to allow statistical analysis and population genetics to be applied to collected biological samples.

WO 2011/119235 A1

METHODS FOR CONDUCTING GENETIC ANALYSIS USING PROTEIN
POLYMORPHISMS

CROSS-REFERENCE TO RELATED APPLICATION

5 This application claims the benefit of U.S. Provisional Application No. 61/340,918, filed March 24, 2010, the disclosure of which is incorporated herein by reference in its entirety.

TECHNICAL FIELD

10 The invention relates to biotechnology and the fields of genetics and proteomics generally, more particularly to the use of marker polypeptides containing polymorphisms to identify individuals and measure genetic relationships.

BACKGROUND

15 Genetic analysis has evolved and become a prevalent component in society. It is used to establish paternity, to identify individuals or human remains and conduct anthropological analysis of genetic diversity within populations and genetic distance between populations. It is used to determine susceptibility to hereditary diseases and in treatment protocols for somatic disease, such as cancer.

20 Molecular genetic analysis however, is almost totally dependent on analysis of deoxyribonucleic acid (DNA). DNA technology has become increasingly sophisticated, sensitive and the threshold for its use has become continually lowered. DNA technology has matured and includes such disparate technology as sequencing technology, polymerase chain reaction (PCR), microarray, and construction and use
25 of DNA libraries. The complete sequence of many genomes has been achieved including human, primates (chimpanzee and orangutan), model organisms (mouse, rat, zebra fish, *drosophila*, *Caenorhabditis elegans*,) and pathogens. Human genomics has identified genetic structures including genes with, exons, introns, and promoter regions and other coding regions responsible for RNA structures. The
30 genome includes non-coding DNA including long interspersed nuclear elements (LINEs), short interspersed nuclear elements (SINEs), retrovirus-like elements and DNA transposon copies. It also includes chromosomal structures such as centromere and telomere-specific sequences.

DNA also exists in mitochondria. This DNA contains fundamental differences to nuclear DNA, it is circular, has a different genetic code and produces only two RNAs, one in each direction, that contain the code for several genes. These features support the accepted hypothesis that mitochondrial DNA originated from endosymbiotic bacteria. The genetics of mitochondrial DNA are matrilineal.

DNA is the basis of genetic variation, which in turn is the basis for the unique phenotype of each individual. Mutations accumulate over each generation and through recombination, independent assortment and zygote formation result in a unique combination in each individual. The variation occurs within each nucleic structure, ranging in size from single nucleotide polymorphisms (SNPs), element insertion, deletion or expansion to chromosomal duplications, deletions and inversions. As it is inherited, this variation maintains a record of an individual's genetic history.

Technology that detects and records genetic variation can provide information for several purposes. It can determine genetic relationships, such as paternity testing, confirming that an individual is descended from two given individuals. DNA can be used to confirm whether a suspect was at a crime scene. A record of unique genetic markers is also used to provide a measure of genetic diversity within a population and a measure of genetic distance between populations. It is also used to determine if an individual is a carrier for a genetic disease or is predicted to be susceptible to a genetic disease. Matching specific DNA markers with a specific inherited disease phenotype has resulted in the discovery of the specific disease genes and the role of many genes in specific disease pathways and physiological mechanisms.

Extensive efforts have been made to record and annotate the human genome and measure the full extent of genetic variation. This resulted in the human genome project and the dbSNP database (www.ncbi.nlm.nih.gov/SNP/), which records human DNA polymorphisms. Using the National Council of Biotechnology Information SNP database it is now possible to obtain the allelic frequency of each SNP in a population-specific manner.

The use of DNA has distinct limitations. If it is collected from volunteers and isolated and stored appropriately it maintains its quality and can be used indefinitely. For many applications however, DNA collection is not ideal. The backbone of DNA consists of phosphodiester bonds that are vulnerable to hydrolytic attack and oxidation. The nucleobases are susceptible to oxidation, alkylation and condensation

2011229918 05 Dec 2014

reactions. Environmental samples from biological remains, forensic samples or anthropological material contain DNA that has not been kept in ideal conditions and is susceptible to chemical and environmental degradation, reducing the quality and integrity of the resulting data. Many applications of DNA, such as use of forensic material, are limited by the frequent absence of DNA or inability to eliminate environmental contamination.

Accordingly, methods of performing analysis on biological samples that utilized a material other than DNA to allow for the collection and preservation of biological samples in circumstances where DNA may not be present or may be degraded, which enable the investigation, establishment, or exclusion of genetic relationships at a level of precision approaching that of DNA analysis would be an improvement in the art. Such a system allowing for the determination of DNA polymorphisms in a biological sample without DNA analysis would further be an improvement in the art.

SUMMARY

The present invention is directed to methods of conducting genetic analysis through protein polymorphisms, including identification of individuals, establishment of paternity and measurement of genetic diversity and distance. Some illustrative embodiments of methods of the present invention include the identification of peptide biomarkers using proteomic techniques, including liquid chromatography-tandem mass spectrometry from biological samples, using hair, dentin, or bone as a source of the protein to be analyzed. Other illustrative embodiments include the determination of allelic frequency and feasibility of protein polymorphism peptide biomarkers, and the application of these frequencies to allow statistical analysis and population genetics to be applied to collected biological samples.

A first aspect of the invention provides a method of using protein polymorphism biomarkers to conduct genetic analysis on a proteinaceous tissue sample, the method comprising:

- extracting a mixture of proteins from the proteinaceous tissue sample;
- digesting the extracted mixture of proteins with trypsin;

identifying a pattern of polymorphic tryptic peptides present within the extracted mixture of proteins; and

analyzing the identified polymorphic tryptic peptides present within the extracted mixture of proteins to make a determination as to a genetic relationship of a source of the proteinaceous tissue sample.

A second aspect of the invention provides a process for conducting genetic analysis on a hair sample, comprising:

extracting a mixture of proteins from the hair sample;

digesting the extracted mixture of proteins with trypsin;

identifying a pattern of tryptic peptides present within the extracted mixture of proteins; and

analyzing the identified pattern of tryptic peptides present within the extracted mixture of proteins to identify protein polymorphisms of interest to make a determination as to a genetic relationship of a source of the hair sample.

DESCRIPTION OF THE DRAWING

It will be appreciated by those of ordinary skill in the art that the drawings are for illustrative purposes only. The nature of the present invention, as well as other embodiments of the present invention, may be more clearly understood by reference to the following detailed description of the invention, to the appended claims, and to the drawings.

Figure 1 is a Table of Candidate Peptide Polymorphic Biomarkers Present in Human Hair. Both reference and polymorphic sequences are present, along with masses and predicted allelic frequencies derived from the HapMap database.

Figure 2 is a table of the 24 most abundant proteins (name, UNIPROT identifier, primary protein citation number) as detected from the method described in Example 1A. Natural variants occurring in each of these gene products are indicated by amino acid missense or nonsense mutation, reference SNP number (rs#), and SwissProt natural variant identifier (FTId#).

Figure 3 is an identification of male specific trypsin-digested peptides in the Y-chromosome isoform of amelogenin.

DESCRIPTION OF THE INVENTION

Before the present method is disclosed and/or described, it is to be understood that it is not limited to specific tissues, method of obtaining protein samples or method of protein measurement or detection. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments and is not intended to be limiting.

As used herein and in the appended claims, the singular forms "a", "an", and "the" include plural reference unless the context clearly dictates otherwise. For example, reference to "a host cell" includes a plurality of such host cells, and reference to the "antibody" is a reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so forth.

As used herein "Peptide," "Polypeptide" and "Protein" include polymers of two or more amino acids of any length, and includes post-translational-modification, without restriction on length unless the context clearly dictates otherwise.

As used herein, "comprising," "including," "containing," "characterized by," and grammatical equivalents thereof are inclusive or open-ended terms that do not exclude additional, unrecited elements or method steps, but also includes the more restrictive terms "consisting of" and "consisting essentially of."

As used herein, "a subject" means a vertebrate, such as a fish (salmon, trout, eel), poultry (chicken), or a mammalian (human, cat, dog, mice, rats, guinea pigs, or other small laboratory animals, or farm animals like ruminants or pigs).

Ranges can be expressed herein as from "about" one particular value, and/or to "about" another particular value. When such a range is expressed, another embodiment includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent "about," it will be understood that the particular value forms another embodiment. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint. It is also understood that there are a number of values disclosed herein, and that each value is also herein disclosed as "about" that particular value in addition to the value itself. For example, if the value "10" is disclosed, then "about 10" is also disclosed. It is also understood that when a value is disclosed that "less than or equal to" the value, "greater than or equal to the value" and possible ranges between values are also disclosed, as appropriately understood by the skilled artisan. For example, if the value "10" is disclosed the "less than or equal to 10" as well as "greater than or equal to 10" is also disclosed. It is also understood that the throughout the application, data is provided in a number of different formats, and that this data, represents endpoints and starting points, and ranges for any combination of the data points. For example, if a particular data point "10" and a particular data point 15 are disclosed, it is understood that greater than, greater than or equal to, less than, less than or equal to, and equal to 10 and 15 are considered disclosed as well as between 10 and 15. It is also understood that each unit between two particular units are also disclosed. For example, if 10 and 15 are disclosed, then 11, 12, 13, and 14 are also disclosed.

In this specification and in the claims which follow, reference will be made to a number of terms which shall be defined to have the following meanings:

"Optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances where it does not.

The term "suitable" as used herein refers to a group that is compatible with the compounds, products, or compositions as provided herein for the stated purpose. Suitability for the stated purpose may be determined by one of ordinary skill in the art using only routine experimentation.

The term "biomarker" as used herein refers to a biological artifact, particularly protein and/or peptide, that is detectable and contains a polymorphism.

The term "detect" as used herein refers to identification of biomarkers and / or properties and / or parameters of the biomarkers including mass, charge, statistical correlation with reference peptides and probability scores.

5 The term "tissue" refers to all biological tissue, including human samples, human remains or mummies, or non-human sources, such as zoological and /or preserved remains.

The term "polymorphism" refers to allelic variation in nucleic acid and/or corresponding protein sequences.

10 As discussed previously herein, the use of DNA for genetic analysis of collected biological samples has distinct limitations. Environmental samples from biological remains, forensic samples or anthropological material contain DNA that has not been kept in ideal conditions and is susceptible to chemical and environmental degradation, reducing the quality and integrity of the resulting data or even the ability to perform analysis. Many applications of DNA, such as use of forensic material, are
15 limited by the frequent absence of DNA in the available biological samples or by the inability to eliminate environmental contamination.

Protein, the translated product of DNA, reflects in an absolute manner the variation present in the coded regions of the genome. Therefore it maintains the genetic variation within the DNA in the form of mutations in the amino acid
20 sequence. It is more abundant than DNA and it has a peptide bond in its backbone resulting in greater chemical stability and longer life in the environment compared to the more fragile DNA. While the earliest credible sequences of DNA are from a 50,000 year old frozen mammoth, proteins have been detected and sequences determined from a 40 million year old hadrosaur.

25 DNA is often not available in human remains that have been exposed to the environment for prolonged periods. However proteins are present beyond the threshold time point of DNA utility. Human remains have proteins present in hard tissues, such as hair, teeth (dentin) and bone that have the potential to be analyzed for polymorphisms, and as such could be used to identify an individual based on parent or
30 sibling DNA, or identity based on other protein samples from the individual. Samples would be obtained from a range of tissues and a wider range of tissue samples. Identification of protein polymorphisms can help determine the genetic distance from a given genetic population, such as a sub-Saharan population.

While protein cannot be amplified, it can be measured with high precision and great sensitivity using mass spectrometry. Protein samples are digested with trypsin, which cleaves the protein into smaller detectable peptides. The peptides are then resolved using very low flow rate liquid chromatography and are ionized and vaporized using electrospray ionization. The charged peptide is then funneled using electric fields into the mass spectrometer where its mass is measured. It is then fragmented using either collision-induced or electron transfer dissociation and the resulting fragment masses are also measured. Both of these fragmentation methods break the peptide backbone at regular points. This allows the amino acid sequence to be determined. The current technology is sensitive enough to detect attomole levels of material at 1 ppm accuracy.

The process of fragmentation data deconvolution has two basic methods. Information may be interpreted using the data within the sample, based on the intrinsic properties of peptide fragmentation, to provide *de novo* sequence information. Alternatively, fragmentation data may be compared with predicted sequences derived from genomic databases. This method provides a statistical measure of probability that any fragmentation dataset is the predicted amino acid sequence. This provides accurate interpretation of fragmentation data and is more reliable than *de novo* sequencing. The accuracy however depends on the presence of the peptide amino acid sequence being in the reference protein database.

The accuracy of amino acid sequencing depends on several factors. The actual sequence needs to be in the reference database. The other factor is the mass accuracy of the mass spectrometer instrument. Ambiguity in the mass data from less accurate instruments results in ambiguity in interpreting the amino acid sequence.

In illustrative methods in accordance with the present invention, biological samples are analyzed by mass spectrometric analysis to obtain peptide sequence data for known proteins in the biological samples. Peptide polymorphisms in the peptide sequence data are then analyzed. In simple situations, the presence or absence of polymorphisms can be used for exclusionary analysis. Where available, the polymorphism data can be compared to known population frequencies using appropriate statistical tools to determine the likelihood of matches and the relative strength of the exclusionary analysis. Suitable biological samples may include hair, bone, dentin, skin or other tissues for which the protein polymorphic data can be assessed.

The following factors need to be considered in identification of peptide polymorphic biomarkers. Suitable biomarkers need to be readily identified in mass spectrometry, as a significant portion of any protein is either not ionized or volatilized resulting in its lack of detection. Preferred polymorphic biomarker peptides should also have a measured informative allelic frequency. Biomarkers should be present in sufficient quantities to be detected in any population. Heterozygosity is also a factor as it may result in non-uniform distribution of polymorphism peptide biomarkers. Several samples therefore should be used to eliminated or confirm the presence of protein polymorphisms, as the utility of allelic frequencies and resulting protein polymorphism biomarkers are a function of degree of sampling taken in the reference population. Since reference databases need to be developed, a lack of adequate sampling could result in inaccurate allelic frequencies leading to inaccurate statistical measurements of identity. Such a shortcoming could be addressed by using multiple markers from a single sample, by use of technique for exclusionary purposes (similar to the rough application of A, AB, B, and O blood types) and ultimately by the continued development of databases containing the requisite frequency data for suitable markers of various proteins in the available samples, as discussed in more detail in the following paragraphs.

In order to be used as a peptide biomarker for a single nucleotide polymorphism ("SNP"), the resulting polymorphic peptides need to be detected. The peptides need to be unique, an issue when investigating the highly homologous family of intermediate filament proteins. Peptides must be unique for a single gene product and nucleotide polymorphism. To be detected peptides need to be within a mass / charge ratio of 400 to 2000. The peptides also need to be volatilized and ionized. Even under ideal conditions coverage of proteins is not 100%, usually being less than 80%. The trypsinized peptides also compete for occupancy for the ion-traps and quadrupoles in the instrument, so detection of given peptides is often contingent on the ionization status of other peptides.

The potential silencing of heterozygotic alleles may also limit the detection of genetic variation. The spatial pattern of gene silencing has the potential to result in non-representative transcription and translation of genetic variation. It also raises the possibility that different hairs from different regions of a single individual may have different expression of polymorphic proteins. Discrimination between homozygotic and heterozygotic alleles may require more than several hair samples from different

regions of the body. Non-detection of another corresponding protein polymorphism cannot be used as evidence of homozygosity. Dependence on allelic frequencies to determine genetic probabilities is not altered by the absence of other allelic variants and therefore provides a more conservative estimate of exclusion or identity.

5 The dependence on single nucleotide polymorphisms reduces the exclusionary power of the genetic analysis. Only four options are available at any loci, almost always only two options occur. The frequencies of these polymorphisms are generally high and rarely at the ideal frequency of 0.5. More instances of polymorphisms are therefore required to reach equivalent powers of exclusion.

10 Currently, the determination of amino acid sequence of peptides is dependent on comparison with predicted sequences from reference databases. The dependence on reference databases therefore results in difficulty in detecting the unexpected. The absence of amino polymorphisms in reference databases results in the absence of polymorphic peptides in the analysis. Detection of polymorphic peptides not in the
15 reference database will require the use of custom databases where whole polymorphic protein variants are incorporated. Careful analysis of error-tolerant searches may also provide insight into polymorphisms in an unbiased manner. Environmental and chemical modifications, such as oxidation and hydrolysis also result in changes in peptide mass and difficulty in interpretation of fragmentation data.

20 The allelic frequencies associated with each nucleotide and amino acid polymorphism are a product of the reference populations used in the single nucleotide polymorphism databases. These can be arbitrary in terms of distribution and sample size. Refinement of allelic frequencies will improve over time as sample sizes of relative populations become sufficient to reduce statistical variation and increase
25 confidence in allelic frequencies for each SNP and respective amino acid polymorphism.

 Maximum discriminating power of this analysis will depend on maximum detection of polymorphic peptides, which is a function of maximum detection of unique peptides in any given sample. To maximize accurate yield of peptides two
30 approaches can be taken, physical detection of peptides may increase and reference databases and their use can become more sophisticated. Broadened detection of peptides results from increased resolution using liquid chromatography, increased frequency of data acquisition, more efficient fragmentation and increased mass accuracy that reduces ambiguous data interpretation. These criteria are currently met

in the latest generation of ultra high resolution quadrapole-time-of-flight mass spectrometry instruments.

Genetic Analysis Using Variation in Human Hair Protein

5 Human hair protein is ubiquitous, continually shed, and chemically stable, lasting in the environment long after DNA has degraded. It is very common at crime scenes. Preliminary data shows that hair contains over 300 detectable proteins. The genes of these proteins contain functional Single Nucleotide Polymorphisms (SNPs) that manifest as missense mutations and occur at measurable allelic frequencies.
10 Therefore, any strand of hair has the potential, in its intrinsic amino acid sequences, to provide a statistically conclusive link to any given individual.

In methods in accordance with the present invention, proteins from hair samples are digested with the protease trypsin, cleaving the protein into peptides with molecular weights of roughly 400 to 4000. The resulting complex peptide mixture is then resolved with reversed-phase liquid chromatography, ionized and volatilized, and directed into a mass spectrometer where masses are determined (MS). The instrument then fragments individual peptide backbones and measures the resulting pieces, which have a distinctive pattern (MS²). The information from mass spectrometry, therefore, has three dimensions: time of retention on reversed phase, peptide mass (MS) and individual peptide fragmentation masses (MS²). Mass spectrometry has matured to the point where over 10,000 peptide fragmentations can be obtained per run. The mass accuracy of peptide and fragmentation masses is now 1ppm in both MS and MS², removing ambiguity from the analysis.
15
20

Proteomic analysis of a hair sample identified 319 proteins at an average of 17.6% coverage. The human genome contains 129,000 non-synonymous or functional single nucleotide polymorphisms (SNPs), 16,766 of which have known allelic frequencies using the Utah and Northern European populations (www.ncbi.nlm.nih.gov/snp/). This is an average of 0.7SNPs per gene which calculates to approximately 230 per the 319 identified proteins. Assuming mass spectrometry coverage of 17.6% we should expect to identify 41 polymorphic peptides per run allowing for meaningful statistical analysis of the resulting discovered polymorphisms. For example, such analysis can be used to confirm or exclude that a hair sample found at a crime scene belongs to a suspect without
25
30

requiring DNA analysis with a precision comparable to current forensic DNA analysis, to identify human remains when no DNA is available, or to establish genetic relationships such as paternity. Other potential uses include tissue matching to genetically distinctive populations, and providing measures of genetic distance.

5 Single nucleotide polymorphisms (SNPs) and insertion / deletions (indels) are also highly abundant in the genome. A recent paper focusing on the use of SNPs to generate measures of identity demonstrated that 30 highly polymorphic SNPs were able to generate a combined mean match probability of 4.83×10^{-13} [1]. Every 5 additional loci would increase the discriminatory power ten-fold. The 1000 genome project records 15,275,256 SNPs and 1,480,877 indels. These are collated in the dbSNP database (www.ncbi.nlm.nih.gov/projects/SNP/) that has a total 30,443,446 *Homo sapiens* SNPs (as of March 18, 2011), 161452 of which are non-synonymous, with 41,928 having an annotated allelic frequency (14,887 when restricted to the Utahn and Northern European population). Assuming that there are 21,000 gene products in the human genome that is an average of roughly 2 genetically informative SNPs per protein. The average protein coverage of the 319 identified proteins from the hair proteome was 17.9%. Therefore the theoretical yield of informative SNPs is roughly 114 ($319 \times 2 \times 0.179$). SNP variation is not evenly distributed however with the 100 most abundant proteins in the hair proteome having 1294 non-synonymous SNPs with 384 having allelic frequencies (70 when restricted to the Utahn, Northern European CEU database). Preliminary analysis of that data, based on the 18 most abundant proteins, identified 61 polymorphic peptides from 52 SNPs.

Genetic Analysis Using Variation in Human Bone and Teeth Protein

25 Human bone and teeth are often all that remains in many archeological and forensic contexts. Protein, however, can be preserved in the collagen/hydroxyapatite mineral matrix of these tissues. There are several ways to extract peptide information from such tissues, including a hand-drill, crushing a block of material under liquid nitrogen and demineralization with EDTA or 1.2 M hydrochloric acid. Extracted proteins may be digested with the protease trypsin, cleaving the protein into peptides with molecular weights of roughly 400 to 4000. The resulting complex peptide mixture may then be resolved with reversed-phase liquid chromatography, and

analyzed similar to the analysis of hair protein previously discussed herein with the identification of suitable proteins for SNP analysis.

In one example, the sex of sub-adult skeletons cannot be identified where other materials are not present as sexually dimorphic skeletal markers develop during adolescence. This is a major barrier to interpretation and analysis of pre-adult remains in anthropological contexts and can be an impediment to the identification of remains in a forensic context. The development of a consistent, reliable sexing protocol has been described as a "Holy Grail" of osteology and physical anthropology for more than 70 years. Tooth dentine usually provides material for identification of matrilineal mitochondrial DNA haplotype and haplogroup, estimates of nucleotide and gene diversity, and the mean number of pairwise differences but contains no information reflecting biological sex. The Y-chromosome however contains an isoform for amelogenin, which plays a major role in the biogenesis of teeth and has several unique peptides, and has identified male-specific trypsin-digested peptides. (FIG. 3.) By examining the proteomic profiles of teeth and bone tissues, the relative proportions of each isoform of amelogenin may be determined. Once a base line for the relative proportions in samples of known sex is established, tissue from remains of unknown sex may be analyzed to determine the sex thereof.

Example 1A. Identification of an individual from a human hair sample and development of allelic frequency comparative database for human hair proteins peptide polymorphisms

Human hair consists of an outer cuticle surrounding a shaft consisting primarily of keratin and keratin associated proteins. Hair is made by specialized keratinocytes in the hair follicle. Internal intermediate filaments build up and encase non-keratin proteins before the cell dies, creating a component of the hair shaft that then progresses toward the skin surface. The insoluble component of hair contains over three hundred proteins, a considerable amount of proteomic information.

Hair is significant forensically because it is prevalent at crime scenes and has the potential to physically link an individual to a particular space and time. The evidence is biological and as such, is highly complex. The current methodology however, struggles to fully utilize the information within hair, which up until now has

been either morphological or genetic. Each type of information has issues however, morphological analysis is intrinsically subjective and genetic information is limited by the low levels and compromised nature of DNA.

5 Human hair originates in papilla cells, which reside in the base of the hair follicle in the hair bulbus. These cells produce large amounts of different keratin proteins that displace cellular contents and ultimately result in the cell undergoing apoptosis. This process includes degradation of nuclear DNA. Prior to apoptosis the keratin molecules develop extensive covalent bonds with neighboring keratin molecules, primarily disulphide bonds and transglutamation between glutamic and lysine residues. This extensive level of covalent bonding is responsible for the chemical toughness and resilience of hair. The transglutamation process is indiscriminate however, many other proteins including metabolic, structural and nuclear proteins, also become covalently attached to, or emmeshed within, the extensive keratin matrix. As described in the literature, there are over 300 proteins detected in the hair shaft, including many proteins that are not normally associated with hair. The keratinization extends beyond the cell through desmosomes and hemidesmosomes. The resulting hair shaft has a variety of anatomical features.

20 Hair growth can be subdivided into three phases: anagen or growth phase, katagen or transitional phase and the final telogen phase. There are about 100,000 hairs on a (non-bald) human scalp of which 70 to 150 telogen hairs are lost per day. As many hairs again are found on the remainder of the body. Most hairs found at a crime scene are almost always telogen hair shafts that do not have follicular cells and have nuclear DNA levels typically below the level of detection. Several groups have tried to analyze the efficacy of obtaining complete or partial nuclear DNA profiles from hair. The use of mini-STRs, dithiothreitol to break disulphide bonds, and novel DNA extraction techniques has had some success with 60% of samples hair providing partial information on some STR loci. Unfortunately, the DNA is typically found to be highly degraded and yields are particularly vulnerable to chemical treatments such as hair dye or bleaching.

30 A comparative database of human hair was developed by analyzing the 24 most abundant proteins in human hair for suitable polymorphisms. Using the UNIPROT database that contains a section of natural variation and provides the associated single nucleotide polymorphism (SNP). Accessing the SNP database

through the UNIPROT database allows the allelic frequency of each particular polymorphism to be determined relative to the reference sequence. This allowed several pieces of information to be obtained about candidate biomarker polymorphism: the Reference SNP (refSNP) Cluster Report number, the single
5 nucleotide polymorphism, the resulting missense mutation or amino acid polymorphism, the predicted peptide amino acid sequence for both reference and missense trypsin-digested peptides (along with their respective masses), and finally the calculated allelic frequency for the SNP that accounts for the amino acid polymorphism.

10 The information obtained from the UNIPROT database allowed for a determination as to the presence of nucleotide polymorphisms in the genome of a given individual based purely on the presence of a biomarker peptide in a hair sample, with no application of DNA-based methodology. Furthermore, the determined allelic frequencies of detected biomarker, as recorded in the NCBI SNP database, were used
15 in combination with other polymorphic peptides to calculate the probability that any hair sample comes from the same individual as another hair sample. Likewise, in additional embodiments, a predicted combination of peptide biomarker polymorphisms could be determined using DNA-based methodology, such as SNP microarray chips or polymerase chain reaction, which could then be confirmed using
20 proteomic methodology.

Method for obtaining allelic frequencies of protein polymorphisms

Human hair proteins identified from literature, or from the sample obtained from a volunteer, provide a description of proteins present in human hair in order of
25 relative probability. Confirmed members of the hair proteome were submitted to the UNIPROT database, which contains a section on Natural Variation listing all known nucleotide variants in the open reading frame of the gene that result in missense mutations. Each missense mutation is annotated along with the responsible single nucleotide polymorphism, with its single nucleotide polymorphism reference number.
30 These numbers are hyperlinked to the National Council of Biotechnology Institute SNP database, which is a general catalog of genetic polymorphism maintained by the NCBI that is publically accessible through the URL:
www.ncbi.nlm.nih.gov/projects/SNP/. Reference numbers herein are from build

release dbSNP build 133, the contents of which are incorporated by reference herein in their entirety.

This database contains, in the geneview section, the annotated nucleotide polymorphism along with the annotated amino acid residue change. The population diversity section of each entry in the database includes information required to derive the allelic frequency of both the nucleotide and amino acid polymorphism. The information comes in several forms, either the frequency of the allelic variant is provided in each reference population or a collated value derived from all populations analyzed. In the case of the former format, the collated value for all populations is determined manually.

As shown in FIG. 1, the UNIPROT and SNP database were used as discussed above to analyze three of these proteins for mis-sense mutations with established allelic frequencies to establish that hair proteins contain evidence of genetic variation. The allelic frequencies of each alternative peptide sequence are depicted in **bold** and the peptides detected with mass spectrometry are indicated in italics.

Preparation of Protein Samples and Mass Spectrometric Analysis

Hair was treated by washing twice for 2 hours in 50 ml of 10% methanol and once with 100% water. Hair was removed and ground with clean exterior of an Erlenmeyer flask on a glass plate. The powder was collected and treated with 50 mM ammonium bicarbonate containing 1% ProteaseMax and DTT (30 mM). The sample was centrifuged and separated into supernatant and insoluble hair fraction. Trypsin (600 ng) was added to both supernatant and the insoluble hair fraction and incubated at 37°C temperature overnight. Digested peptide mixture (1 μL of 150 μL) was injected directly on to the ESI Ion-Trap/FTMS hybrid mass spectrometer (LTQ-FT, ThermoElectron, Corp., Waltham, MA) without further purification.

An aliquot of 1 μl of the sample was injected onto a nano-LC column (75 μm ID x 10 cm, Atlantis C18 RP, 3 μm particle size, Waters, Milford, MA) using a nano-LC system (NanoLC 1D, Eksigent Technologies, Dublin, CA) with a gradient of 9% to 60% acetonitrile in 0.1% formic acid at 400 nL/min (Supplemental Table 1A) over 120 minutes. Primary mass spectra were acquired in the FTMS portion of the instrument and MS/MS sequence information was collected in the linear ion trap using collision-induced dissociation (CID). Primary mass spectra were acquired with

typically better than 2 ppm mass accuracy; CID fragmentation spectra were acquired with less than 0.3 Da mass error.

Data Analysis

5 Peaklists for database searching were generated for peptide precursor ions (i.e. +1, +2 and/or +3 charge states) and corresponding CID fragmentation data using SEQUEST (BioWorks Browser, revision 3.2, ThermoElectron Corp.) with the default parameters. Resulting DTA files from individual LC/MS/MS runs for each species are concatenated into a single file and analyzed using MASCOT (software version 10 2.1.03, Matrix Science, Inc., Boston, MA). The following MASCOT search parameters were used in the analysis: tryptic-specific peptides, maximum of 3 missed cleavages, no fixed modifications, variable methionine oxidation, mass tolerances of 5 ppm for precursor ions and 0.3 Da for MS/MS CID fragment ions. A significance threshold of $p < 0.05$ for identified proteins was used. Individually identified peptides 15 with expectation scores below 0.05 were considered significant and included. Any protein or peptide with greater than a 5% chance of false assignment were excluded. In order to be classed as a glycogen-associated protein, two unique peptides, with different primary sequence and expectation scores less than 0.05, were required to be identified from the gene product.

20 The probabilities of identity using allelic frequencies were then determined and polymorphic-tryptic peptides were identified. The output from proteomic analysis depends on comparison of peptide and fragmentation masses with those in the reference genomic and proteomic databases. Each match is amenable to statistical analysis, resulting in a probability that the match is incorrect (expectation score < 0.05 = significant) and a score of likelihood (MOWSE score). Raw mass spectrometric data, usually in an application specific format, is therefore converted to peptide sequences, which in turn are matched to proteins present in the reference databases. The peptides present in the sample can then be matched to those predicted to represent polymorphic variation as described in the above paragraph. The associated 25 frequencies of these polymorphic peptides are depicted in TABLE 1 and can be statistically assessed to provide a probability that a particular hair is associated with a given individuals. One assessment that can be used is Random Match Probability, which is useful as a method of stating the rarity of a genetic profile, as set forth beginning at page 243 of the reference manual Fundamental of Forensic DNA Typing

30

by John M. Butler, Elsevier 2010, the contents of which manual are incorporated by reference herein in their entirety.

TABLE I

5

Desmoplakin		
R1738Q	SEADSDK SEQ ID NO: 1	0.758
G5492A	GQSEADSDK SEQ ID NO: 2	0.234
rs6929069		
Keratin, type I cuticular Ha2		
T395M	LEGEINTYR SEQ ID NO: 3	0.629
C1245T	LEGEINMYR SEQ ID NO: 4	0.371
rs2071563		
Plakophilin-1		
R116H	FSSYSQMENWSR SEQ ID NO: 5	0.975
G598A	HFSSYSQMENWSR SEQ ID NO: 6	0.024
rs34626929		
Stratifin		
M155I	SAYQEAMDISK SEQ ID NO: 7	0.998
G536A	SAYQEAIIDISK SEQ ID NO: 8	0.003
rs11542705		
Keratin, type I cytoskeletal 39		
L383M	QNQEYEILLDVK SEQ ID NO: 9	0.876
C1183A	QNQEYEILMDVK SEQ ID NO: 10	0.124
rs17843023		
Protein-glutamine gamma-glutamyltransferase		
G843A	SWNGSVEILK SEQ ID NO: 11	0.821
S249N	NWNGSVEILK SEQ ID NO: 12	0.133
rs214814		
Keratin, type II cuticular Hb3		
C900G	DLNMDCIVAEIK SEQ ID NO: 13	0.981
I279M	DLNMDCMVAEIK SEQ ID NO: 14	0.019
rs2852464		
Bleomycin hydrolase		
I443V	HVPEEVLAVLEQEPIILPAWDPMGALA SEQ ID NO: 15	0.646
A1564G	HVPEEVLAVLEQEPIVLPWDPMGALA SEQ ID NO: 16	0.305
rs1050565		
L-lactate dehydrogenase A chain		
S161R	VIGSGCNLDSAR SEQ ID NO: 17	0.276
C755G	GCNLDSAR SEQ ID NO: 18	0.724
rs5030621		

Example 1B. Further development of an allelic frequency comparative database for human hair proteins peptide polymorphisms

5 A volunteer's hair was washed thoroughly with water and 20% methanol and digested with trypsin in the presence of Protease-Max (Promega Inc.). The resulting peptides were applied to a Thermo-Finnigan Hybrid LC/LTQ/FT MS. The resulting data file was submitted to the MASCOT algorithm using a custom reference database that incorporated some protein polymorphisms. 319 proteins were identified (from
10 7400 peptides) with an average protein coverage of 20%. The resulting data was searched for polymorphic peptides corresponding to the 40 identified proteins. The results of which are depicted in TABLE II.

In TABLE II, the polymorphic peptides identified in the sample are listed along with the biallelic sequence and the responsible non-synonymous single
15 nucleotide polymorphism (rs#). Allelic frequencies are indicated where known. Each peptide was analyzed for quality of assignment (expectation scores below 0.05 that indicates acceptably low probability of incorrect peptide assignment ($p = 0.05$)), and was submitted to the PROWL database to determine if the sequence could be unambiguously assigned to a single gene. Peptides that were correctly assigned and
20 unambiguous are indicated by allelic frequencies being boxed and in bold. These frequencies may be assessed by Random Match Probability to determine the rarity of a profile. In doing such assessment, it may be advantageous to discard frequencies greater than 0.65 in order to remove the most commonly shared alleles from the analysis to improve the sensitivity of the assessment. Using the data from TABLE II
25 in such an analysis calculates a Random Match Probability of 0.025 or 1 in 40.

TABLE II

Detected Polymorphic Hair Peptides	allelic frequency	Keratin type I cuticular Hb3-II	Q14225
Desmoglein 1 isoform 1 P15924			
rs80325569	NLMSEISGK SEQ ID NO: 19 NLMSEISSK SEQ ID NO: 20	rs12450621	DNAELENLR SEQ ID NO: 51 DNAELK:NLIR SEQ ID NO: 52
rs77758574	TTIHQLTMQK SEQ ID NO: 21 TTIHQLTMQKEEDTSGYR SEQ ID NO: 22 TTIHQLSMQK SEQ ID NO: 23	rs61741663	LNVEVDAAPAVDLNQLVNETR SEQ ID NO: 53 LNVEVDAAPAVDLNR:VLNETR SEQ ID NO: 54
rs28763966	ANSSATETINK SEQ ID NO: 24 ANSSATETIKK SEQ ID NO: 25	rs79296577	QVVSSSEQLSYQAEIHLR SEQ ID NO: 50 N.D. QVVSSEQLQSYQVEBELR SEQ ID NO: 56
rs28763967	VQEQELTRLR SEQ ID NO: 25 VQEQELTCLR SEQ ID NO: 27	rs114488848	TYNALEIELQAQHNLR SEQ ID NO: 57 0.983 TLNALEIELQAQHNLR SEQ ID NO: 58 0.017
rs6929069	SEADSDKNATILELR SEQ ID NO: 28 LEYDLRRGQSEADSDK SEQ ID NO: 29	rs71373411	YSLENTLTFEPEAR SEQ ID NO: 59 0.9 DSLENTLTFEPEAR SEQ ID NO: 60 0.1
rs116888866	ISITEGIER SEQ ID NO: 30 ISITEGIEQLVDSITGQR SEQ ID NO: 31	rs34771886	YSSQLSQVQSUTNVESQLAEIR SEQ ID NO: 61 0.5 YSSQLSQVQSUTNVESQLAEIHSDLER SEQ ID NO: 62 0.5
Keratin type II cuticular Hb6 Q43790		Selenium-binding protein 3 Q13228	
rs111429470	LYEEER SEQ ID NO: 32 WLYEEER SEQ ID NO: 33	rs72710112	GGPVQVLEDFELK SEQ ID NO: 63 0.992 GGPVQVLEDK SEQ ID NO: 64 0.008
rs61914259	VLQSHISDTVVVK SEQ ID NO: 34 ILQSHISDTVVVK SEQ ID NO: 35		
Keratin type II cuticular Hb5 P78386		Keratin type II cuticular Hb2 Q9NS64	
rs112554450	EAECEADSGR SEQ ID NO: 36 EAECEANSGR SEQ ID NO: 37	rs61730589	ELDVDGIAEIK SEQ ID NO: 65 0.986 ELDVDSIAEIK SEQ ID NO: 66 0.014
rs61740813	DVDCAYLR SEQ ID NO: 38 DVDGAYLR SEQ ID NO: 39	rs74942852	NEILEMNK SEQ ID NO: 67 0.989 K:EIEMNK SEQ ID NO: 68 0.011
rs117675131	SSSFSCGSSR SEQ ID NO: 40 QITSGPSAIGGSITVAPDSCAPCQPL SSSFSCGSSR SEQ ID NO: 41		
Keratin type II cuticular Hb1 Q14533		Biotinylated hydrolase	
rs6580873	LYEEELQLQSHISDTVVVK SEQ ID NO: 42 0.173 LYEEER SEQ ID NO: 43 0.827 ILQSHISDTVVVK SEQ ID NO: 44 0.827	I443V	HVPEEVLAVLEQEPILPAWDFMGALA SEQ ID NO: 15 0.648
rs4761786	HGETLR SEQ ID NO: 45 HGETLCR SEQ ID NO: 46	A1564G	HVPEEVLAVLEQEPVLPWDFMGALA SEQ ID NO: 16 0.305
rs2071588	GLTGGFGSHSVCCGFR SEQ ID NO: 47 GLTGGFGSHSVCCGR SEQ ID NO: 48		
rs57419521	LLEGEEQR SEQ ID NO: 49 LLEGK:EQR SEQ ID NO: 50		

TABLE II (cont.)

Keratin, type I cuticular Ha2		Q14532	
	ETMQFLNDR SEQ ID NO: 69	0.992	
rs117304287	EIMQFLNDR SEQ ID NO: 70	0.017	
	TIEELQKQ SEQ ID NO: 71	1	
rs1111168	TIDELQKQ SEQ ID NO: 72	0	
rs1111169	TIEQLQKQ SEQ ID NO: 73	N.D.	
	MVVNIDNAK SEQ ID NO: 74	0.996	
rs2071560	MVVNTONAK SEQ ID NO: 75	0.004	
	TVNTELELQAQHSLR SEQ ID NO: 76	0.975	
rs57682233	CTVNTLELELQAQHSLR SEQ ID NO: 77	0.025	
	DSLENLSEAR SEQ ID NO: 78	0.996	
rs16966929	DSLENMLTESEAR SEQ ID NO: 79	0.004	
	YSSQLAQMQCMITNVEAQLAEIR SEQ ID NO: 80	0.925	
rs11078993	YSSQLAQMQCMITNVEAQLAEIQADLER SEQ ID NO: 81	0.075	
	ADLER SEQ ID NO: 82	0.9	
rs2604956	AELER SEQ ID NO: 83	0.1	
	AELERQNEQYQVLLDDVR SEQ ID NO: 84	0.1	
	LEGEINTYR SEQ ID NO: 3	0.492	
rs2071563	ARLEGEINTYR SEQ ID NO: 85	0.492	
	LEGEINMYR SEQ ID NO: 4	0.508	
	SLENEQCK SEQ ID NO: 86	0.308	
rs2604955	SLESEQCK SEQ ID NO: 87	0.692	
14-3-3 protein sigma		P31947	
	SAYQEAMDISK SEQ ID NO: 88	0.998	
rs11542705	SAYQEADISK SEQ ID NO: 89	0.002	
	NLLSVAYK SEQ ID NO: 90	N.D.	
rs77608477	NLLSAAYK SEQ ID NO: 91	N.D.	
	SAYQEAMDISK SEQ ID NO: 88	1	
rs78707984	LAYQEAMDISK SEQ ID NO: 92	N.D.	
rs11542705	SAYQEADISK SEQ ID NO: 93	0	
	EMPPTNPIR SEQ ID NO: 94	N.D.	
rs7775255	EMPPSNPIR SEQ ID NO: 95	N.D.	
rs75914997	EMPPTNTIR SEQ ID NO: 96	N.D.	
Desmoglein-4		Q86SJ6	
	GEDLERPLELR SEQ ID NO: 97	0.992	
rs76399598	GEDLESPLLR SEQ ID NO: 98	0.008	
	VLDVNDNFPTLEK SEQ ID NO: 99	N.D.	
rs28380882	VLDVNDNFPALK SEQ ID NO: 100	N.D.	
	NQADFHYSVASQFQMHPTPVR SEQ ID NO: 101	N.D.	
rs76349777	QADFHYSVASQFQMNPTPVR SEQ ID NO: 102		
	GSSLLNYVLGTYTAIDLDTGNPATDVR SEQ ID NO: 103	0.983	
rs35378785	SLLNYVLGTYTAIDLDTGNPATDVR SEQ ID NO: 104	0.017	
	SSTMGLR SEQ ID NO: 105	0.942	
rs61734847	SSTMGALR SEQ ID NO: 106	0.058	
ATP synthase subunit alpha, mitochondrial		P25705	
	ILGADTSVDLEETGR SEQ ID NO: 107	1	
rs11541932	ILGADTSVDIEETGR SEQ ID NO: 108	0	
	AVDSLVPGR SEQ ID NO: 109	0.903	
rs76002505	AVDSFVPIGR SEQ ID NO: 110	0.097	
	TSIAIDTIINQK SEQ ID NO: 111	0.986	
rs77958705/rs77958705	TSIAVDTIINQK SEQ ID NO: 112	0.014	
	EVAFAQFGSDLDAATQQLSR SEQ ID NO: 113	1	
rs11541934	EVAFAQ SEQ ID NO: 114	0	
	QGQYSPMAIEEQVAVIYAGVRYLDK SEQ ID NO: 115	0.847	
rs75974428	QGQYSPMAI SEQ ID NO: 116	0.153	
Annexin A2		P07355	
	DALNIETAIK SEQ ID NO: 117	0.917	
rs75993598	DALNIK:TAIK SEQ ID NO: 118	0.083	
	SALSGHLETIVLGLLK SEQ ID NO: 119	0.865	
rs17845226	SALSGHLETILGLLK SEQ ID NO: 120	0.135	
rs1059688	TDLEKDIISDTSQDFRK SEQ ID NO: 121	N.D.	
rs41307613	DIISGTSQDFR SEQ ID NO: 122	N.D.	
Leucine-rich repeat-containing protein 15		Q8TF66	
	ELSLGIFGMPNLR SEQ ID NO: 123	0.7	
rs13070515	ELSPGIFGMPNLR SEQ ID NO: 124	0.3	

5

The human hair proteins identified from this analysis are added to the comparative database of abundant proteins in human hair with suitable polymorphisms. Accessing the SNP database through the UNIPROT database allows

the allelic frequency of each particular polymorphism to be determined relative to the reference sequence. This allowed several pieces of information to be obtained about candidate biomarker polymorphism: the Reference SNP (refSNP) Cluster Report number, the single nucleotide polymorphism, the resulting missense mutation or amino acid polymorphism, the predicted peptide amino acid sequence for both reference and missense trypsin-digested peptides (along with their respective masses), and finally the calculated allelic frequency for the SNP that accounts for the amino acid polymorphism. The inclusion of the additional suitable proteins allows for a higher degree of accuracy when analyzing hair samples.

Example 1C development of additional database

An initial comparative database of human hair was developed by analyzing the 24 most abundant proteins in human hair for suitable polymorphisms as detected from the method described in Example 1A. Using the UNIPROT database that contains a section of natural variation and provides the associated single nucleotide polymorphism (SNP). Accessing the SNP database through the UNIPROT database allows the allelic frequency of each particular polymorphism to be determined relative to the reference sequence. This allowed several pieces of information to be obtained about candidate biomarker polymorphism: the Reference SNP (refSNP) Cluster Report number, the single nucleotide polymorphism, the resulting missense mutation or amino acid polymorphism, the predicted peptide amino acid sequence for both reference and missense trypsin-digested peptides (along with their respective masses), and finally the calculated allelic frequency for the SNP that accounts for the amino acid polymorphism.

The information obtained from the UNIPROT database allowed for a determination as to the presence of nucleotide polymorphisms in the genome of a given individual based purely on the presence of a biomarker peptide a hair sample, with no application of DNA-based methodology. Furthermore, the determined allelic frequencies of detected biomarker, as recorded in the NCBI SNP database, were used in combination with other polymorphic peptides to calculate the probability that any hair sample comes from the same individual as another hair sample. Likewise, in additional embodiments, a predicted combination of peptide biomarker polymorphisms could be determined using DNA-based methodology, such as SNP

microarray chips or polymerase chain reaction, which could then be confirmed using proteomic methodology.

A Table of the 24 most abundant proteins (name, UNIPROT identifier, primary protein citation number) is set forth in FIG. 2. Natural variants occurring in each of these gene products are indicated by amino acid missense or nonsense mutation, reference SNP number (rs#), and SwissProt natural variant identifier (FTId#). This preliminary data may be further built upon, as shown by the results of Example 1B. To further build the database a comprehensive study on a cohort of samples is conducted. Hair and DNA are obtained from 12 unrelated volunteers and two parents and four children. Hair samples are processed as set forth above in Examples 1A or 1B including trypsin cleavage and mass spectral analysis.

The protein identity and peptide coverage in hair samples are confirmed and the polymorphic peptides are identified to create a reference database with all possible missense mutations. The identified polymorphisms are then confirmed using DNA SNP analysis. A custom chip of equivalent responsible SNPs (384 SNPs) is designed once protein polymorphisms are detected and DNA from all human subjects analyzed.

A list of different DNA variants that may be used for identification of individuals using human hair protein follows below. Each is identified by a reference SNP number (rs#) from the NCBI SNP database, build release dbSNP build 133, which is publically accessible through the URL: www.ncbi.nlm.nih.gov/projects/SNP/ and the contents of which are incorporated by reference herein in their entirety. These have been identified by searching the database for SNPs related to hair proteins that relate to an by amino acid missense or nonsense mutation resulting in a peptide difference that may be detectable in a hair sample using a method in accordance with the principles of the present invention.

rs121918354, rs121913415, rs121913414, rs121913413, rs121913412, rs121913411, rs121913410, rs121913409, rs121913408, rs121913407, rs121913406, rs121913405, rs121913404, rs121913403, rs121913402, rs121913401, rs121913400, rs121913399, rs121913398, rs121913397, rs121913396, rs121913395, rs121913394, rs121913228, rs118203897, rs118203896, rs118203895, rs113994177, rs113994176, rs114998364, rs113905463, rs45581032, rs7272340, rs52800893, rs6048066, rs1126816, rs1126815, rs1042617, rs17313209, rs58885596, rs214830, rs57982162, rs214814, rs60904394, rs52815802, rs3844903, rs214803, rs116974883, rs114174651, rs113688813, rs76914868, rs76252955, rs35987350, rs35967493,

rs35805642, rs11544962, rs57010936, rs2305108, rs3852912, rs2230560,
rs117814881, rs117748961, rs117510013, rs115454241, rs114001067, rs113413186,
rs113320733, rs113255372, rs112942400, rs112743184, rs112548402, rs112376128,
rs111954087, rs79554307, rs79011243, rs77958705, rs77926733, rs76399598,
5 rs76349777, rs76002505, rs75974428, rs74896702, rs61734847, rs60800275,
rs36040686, rs35547948, rs35378785, rs34620697, rs34413638, rs28380082,
rs17856350, rs17856349, rs52806211, rs13381457, rs11874681, rs11541939,
rs11541935, rs11541934, rs52814215, rs11541932, rs11541931, rs11541929,
rs11541928, rs11541926, rs52813728, rs7229252, rs57544609, rs58134049,
10 rs17716472, rs4799570, rs117891115, rs117610737, rs117304287, rs117138331,
rs117083040, rs116901031, rs116384015, rs116221624, rs116216460, rs116116504,
rs115962974, rs115806588, rs115778641, rs115680799, rs115534630, rs115505212,
rs115137098, rs114643360, rs114488848, rs114467326, rs114453622, rs114438618,
rs114422156, rs114395985, rs114289459, rs114125651, rs113931914, rs113879590,
15 rs113833688, rs113792465, rs112895156, rs112831734, rs112806006, rs112787493,
rs112570296, rs112553892, rs112544857, rs112475590, rs112444332, rs112308890,
rs112065669, rs112018671, rs111993782, rs111918281, rs111861376, rs111531747,
rs111344340, rs111342287, rs79955632, rs79843431, rs79458943, rs79320768,
rs79296577, rs78437817, rs78297802, rs77919366, rs77906668, rs77779192,
20 rs77688767, rs77277754, rs76423373, rs76416187, rs75952379, rs75790652,
rs74605551, rs73983451, rs72830046, rs72471582, rs72074479, rs71672421,
rs71373411, rs70964671, rs67537422, rs67537421, rs62642482, rs62642478,
rs62642477, rs62066570, rs61747622, rs61741664, rs61741663, rs61741661,
rs61741660, rs61740669, rs61740668, rs61740667, rs61738272, rs61735162,
25 rs61460100, rs61434181, rs61157095, rs60712939, rs60118264, rs60035576,
rs59878153, rs59616921, rs59510579, rs59317143, rs59296273, rs59175042,
rs59075499, rs58901407, rs58852768, rs58735429, rs58597584, rs58414354,
rs58149344, rs58120120, rs58075662, rs58026994, rs57989439, rs57909628,
rs57784225, rs57758262, rs57682233, rs57536312, rs57019720, rs56809156,
30 rs56707768, rs45557233, rs45546335, rs45507397, rs45489599, rs45444391,
rs41283425, rs41283367, rs41283363, rs36019136, rs35710360, rs35291793,
rs35285640, rs34771886, rs34548975, rs34528587, rs34293483, rs34151210,
rs34137556, rs34019652, rs57516142, rs28940896, rs28674800, rs28411890,
rs17855788, rs28470825, rs17855579, rs17850807, rs17848949, rs17848948,

rs17848946, rs17848945, rs17848929, rs59902640, rs52800237, rs16966929,
rs12947361, rs12947055, rs12946178, rs12937519, rs59654549, rs12451652,
rs12450621, rs12051598, rs11657323, rs11552917, rs11552915, rs11550612,
rs11547397, rs11547396, rs11547395, rs11547392, rs11547391, rs11547388,
5 rs11546666, rs11275186, rs11268553, rs59123042, rs11078993, rs52836971,
rs9904102, rs9903686, rs9903685, rs9893787, rs9890362, rs52822034, rs9675246,
rs16966743, rs57751946, rs8082683, rs61020583, rs16966742, rs52822833,
rs8069943, rs6503628, rs6503627, rs52807316, rs4595852, rs4363911, rs17857021,
rs4261597, rs57183809, rs3744786, rs2604956, rs60774372, rs2604955, rs3809883,
10 rs57617862, rs2604953, rs59835513, rs17581044, rs2301354, rs61572775,
rs16966705, rs17859323, rs17846298, rs2239710, rs2229426, rs11550610,
rs2229425, rs2229424, rs2229423, rs2229421, rs2228309, rs2228307, rs2228306,
rs11550613, rs2228305, rs60687291, rs2071601, rs2071599, rs58844466,
rs52800623, rs2071563, rs52794180, rs60448298, rs2071561, rs52810265,
15 rs2071560, rs1140623, rs1140618, rs1140617, rs17845140, rs17857943, rs17848957,
rs17400684, rs2228308, rs8069426, rs3204598, rs1140616, rs1140614, rs1140613,
rs1140612, rs1140610, rs1140606, rs3192906, rs1132269, rs1132268, rs1132265,
rs1132264, rs1132259, rs1132258, rs60597381, rs17858152, rs17857559,
rs17844847, rs52834590, rs12937241, rs17415687, rs2230409, rs3182084,
20 rs1126821, rs1111169, rs52829742, rs1111168, rs17495901, rs57843904,
rs52830500, rs743686, rs112954819, rs111353136, rs75993598, rs61753428,
rs61731567, rs61731034, rs61731031, rs61730842, rs59430203, rs41307613,
rs35211583, rs35011360, rs17853396, rs17852168, rs17858041, rs17845226,
rs11558375, rs11558370, rs11558365, rs11558360, rs11558358, rs11558354,
25 rs11558352, rs11558351, rs11553794, rs2959910, rs1803909, rs17038531,
rs1061241, rs3202288, rs10514, rs117030850, rs113552509, rs111528910,
rs111281457, rs45545942, rs45462598, rs61755721, rs45456191, rs45447398,
rs17853552, rs17853550, rs11551981, rs11551980, rs11551977, rs11551976,
rs11538647, rs52820499, rs10148371, rs17846167, rs17859177, rs1063391,
30 rs3182352, rs1042918, rs3182308, rs1042869, rs11538650, rs1126860, rs3182151,
rs17354346, rs17295916, rs11125, rs11001, rs59032052, rs17349557, rs17857427,
rs1042188, rs2075600, rs4652, rs61570076, rs2075599, rs3181581, rs17253709,
rs17854838, rs4644, rs113780307, rs111398723, rs61736053, rs61945045,
rs36216107, rs41290740, rs36215077, rs17076703, rs11554039, rs17076692,

rs9511894, rs3764136, rs36216909, rs52836735, rs17790596, rs1803092,
rs117820873, rs117675131, rs117108628, rs116444444, rs116003276, rs115379586,
rs115355093, rs114920447, rs114447073, rs113612324, rs113592710, rs113341953,
rs113026141, rs112554450, rs111866984, rs111540940, rs79897879, rs78482853,
5 rs77846840, rs77331319, rs77154254, rs76972814, rs76579608, rs76412202,
rs75818265, rs75808403, rs75723740, rs75711771, rs75007002, rs74942852,
rs74773270, rs74660757, rs74407849, rs74095618, rs72351593, rs71791446,
rs71764183, rs71445558, rs67486530, rs67486529, rs66529359, rs61917869,
rs61740813, rs61740690, rs61730591, rs61730590, rs61730589, rs61730588,
10 rs61730587, rs61731785, rs61630004, rs61622714, rs61616632, rs61549035,
rs61485872, rs61226348, rs61218439, rs60937700, rs60765982, rs60537449,
rs60526003, rs60447237, rs60359468, rs60297570, rs60279707, rs60022878,
rs59612842, rs59431558, rs59429455, rs59208902, rs59169454, rs59151464,
rs59089201, rs59044845, rs59022806, rs58949162, rs58928370, rs58773503,
15 rs58453920, rs58422839, rs58420087, rs58381018, rs58373389, rs58193503,
rs58062863, rs58008716, rs57977969, rs57959072, rs57837128, rs57802288,
rs57728941, rs57695159, rs57650413, rs57510142, rs57419521, rs57149265,
rs56914602, rs56850150, rs56829062, rs56821304, rs56033871, rs56003009,
rs45541435, rs41291993, rs35699102, rs35460727, rs35460418, rs35353807,
20 rs35124031, rs35043606, rs34787940, rs34187924, rs17678945, rs11550253,
rs11550252, rs11550251, rs11550247, rs11550246, rs11550245, rs11549369,
rs11549361, rs11549352, rs11549351, rs45486301, rs11549349, rs11549348,
rs11549346, rs11549345, rs11549343, rs11549364, rs11549340, rs11549338,
rs11549336, rs11549334, rs11549333, rs11549329, rs11549328, rs11549326,
25 rs11549323, rs11549322, rs11549321, rs11549316, rs11547927, rs11547926,
rs11547925, rs11547923, rs11547922, rs11542649, rs11542647, rs11542646,
rs11542645, rs11542644, rs11542643, rs11170114, rs11064463, rs52791179,
rs7966339, rs7315516, rs52831436, rs17433505, rs59358781, rs6580873, rs4761786,
rs3211600, rs59455799, rs2857671, rs59371060, rs59248948, rs17368348,
30 rs56529229, rs3741714, rs2857663, rs2852471, rs2852470, rs17368026, rs57859988,
rs2852464, rs2741152, rs52836177, rs17715642, rs57500516, rs3741733, rs2658658,
rs61489199, rs2634041, rs2293450, rs2232557, rs2232551, rs2071588, rs1803625,
rs1803619, rs1791634, rs52817241, rs1732263, rs1065740, rs1064903, rs1062442,
rs3203505, rs1062436, rs3203500, rs1062429, rs3168670, rs1062136, rs52834149,

rs3759354, rs1057077, rs59527601, rs1050872, rs3181476, rs1042001, rs60356840,
rs56597060, rs52833239, rs17788615, rs3168597, rs710415, rs52792934,
rs17677668, rs57390569, rs638043, rs15140, rs17855875, rs52799434, rs3825223,
rs3191224, rs1050879, rs14024, rs2230021, rs4134524, rs4986830, rs60823674,
5 rs671, rs116841148, rs113872756, rs113852684, rs113784642, rs113765121,
rs113723438, rs113545301, rs79659860, rs79278408, rs77752215, rs76414276,
rs75739900, rs73400573, rs71705512, rs61876286, rs34305721, rs11604287,
rs11553874, rs11553873, rs11553866, rs11551611, rs11551608, rs11551606,
rs11551605, rs11551604, rs11551603, rs11551602, rs11551599, rs11551598,
10 rs5030621, rs3210555, rs77029930, rs75808734, rs11595614, rs11595592,
rs11557447, rs11557445, rs11557441, rs2231420, rs118101319, rs115257218,
rs114863646, rs114824906, rs79731156, rs77527276, rs77384477, rs76828840,
rs76517216, rs62580623, rs61999288, rs61755726, rs61740953, rs56136100,
rs35356639, rs13298809, rs11545615, rs11545614, rs11545611, rs11545608,
15 rs11545606, rs11545604, rs11542739, rs11542738, rs52832096, rs9330200,
rs4073101, rs9897, rs75629244, rs3204631, rs17413881, rs1051231, rs117775328,
rs117441660, rs111879470, rs104894003, rs61747111, rs36081609, rs17851374,
rs17850166, rs17850033, rs59308417, rs17849553, rs11547706, rs11546945,
rs11546944, rs11546938, rs11546937, rs11546934, rs11546932, rs11546931,
20 rs11546930, rs11546929, rs11546925, rs11546921, rs11546916, rs11546914,
rs11546913, rs11546912, rs11546910, rs11546904, rs11546903, rs11546902,
rs11546901, rs11546899, rs11546898, rs11546895, rs11546894, rs11538804,
rs11538802, rs11538800, rs9769523, rs1059983, rs1133136, rs3178297, rs3194633,
rs58254690, rs17350089, rs10256, rs117961973, rs116888866, rs116640800,
25 rs115924520, rs115913473, rs115149625, rs115044490, rs114698706, rs114396009,
rs114182342, rs114043911, rs113967308, rs113902911, rs113889645, rs113597419,
rs113378925, rs113094932, rs113093944, rs112927420, rs112764594, rs112515836,
rs112242645, rs111368396, rs80325569, rs80084141, rs79671583, rs79541520,
rs78652302, rs77758574, rs77607116, rs76823038, rs76322151, rs76191712,
30 rs75823494, rs75537269, rs75255708, rs73386641, rs73349469, rs66469215,
rs61978632, rs61742483, rs61737311, rs61731476, rs45579941, rs41302885,
rs41302883, rs41266815, rs41266813, rs36082484, rs36043209, rs36026202,
rs35209214, rs35075242, rs34884895, rs34738426, rs34543842, rs34476546,
rs34334797, rs34239595, rs34238014, rs34144478, rs28931610, rs28763971,

rs28763967, rs28763966, rs28763965, rs28763961, rs28763958, rs28521706,
rs58060459, rs28408581, rs52834913, rs17604693, rs13212226, rs13195710,
rs11970638, rs11556692, rs11556658, rs11550843, rs11550840, rs11550818,
rs11550816, rs11550811, rs11550792, rs11550789, rs11550267, rs11550259,
5 rs11547330, rs9503469, rs58684673, rs7766641, rs61346221, rs52837086,
rs6929069, rs3210532, rs2882585, rs2491080, rs2491079, rs52819261, rs2298090,
rs2223591, rs52792530, rs57440467, rs2076299, rs2050949, rs1804839, rs1142845,
rs1045614, rs6457453, rs12193267, rs562047, rs3899064, rs483638, rs75873002,
rs62641703, rs62623676, rs35655433, rs3175026, rs117047588, rs116413867,
10 rs116058101, rs115716405, rs115653853, rs115555466, rs115366708, rs113411271,
rs113243841, rs112573338, rs111979102, rs79479993, rs78861435, rs78426951,
rs78142768, rs77750814, rs77624106, rs77064436, rs76189552, rs75495843,
rs74795266, rs71811389, rs68115727, rs68115726, rs67701986, rs67701985,
rs67701984, rs67701983, rs67701982, rs67701981, rs67701980, rs62240055,
15 rs61755441, rs35523547, rs35288908, rs28931589, rs28931588, rs52793039,
rs61442620, rs13070515, rs13060627, rs9837637, rs5848341, rs5848340, rs5848339,
rs5848338, rs5848337, rs5848336, rs5848327, rs5848326, rs5848324, rs5848323,
rs5848321, rs5848320, rs5848316, rs4135384, rs2364793, rs2364792, rs2364791,
rs5848325, rs2364790, rs5848322, rs2364789, rs2364788, rs1131354, rs1050869,
20 rs52803102, rs933135, rs115025658, rs112713797, rs112113500, rs111523825,
rs80231183, rs78564312, rs76460220, rs72992288, rs72466451, rs67967266,
rs66468541, rs61755731, rs61752176, rs41265953, rs17854949, rs11551350,
rs11551347, rs11551345, rs11551342, rs11547647, rs60998476, rs17849710,
rs16841870, rs58723229, rs8539, rs116396590, rs113410388, rs112477608,
25 rs112455697, rs111401841, rs80338938, rs79984509, rs79907212, rs79128166,
rs78707984, rs78672252, rs78314242, rs77893096, rs77890130, rs77755255,
rs77608477, rs76556156, rs76376996, rs76363140, rs75914997, rs74136386,
rs72710112, rs71732803, rs71640200, rs71630616, rs66704200, rs66704199,
rs62636507, rs62636506, rs62624468, rs61818256, rs61693978, rs61672878,
30 rs61661343, rs61616775, rs61578124, rs61527854, rs61501994, rs61444459,
rs61726480, rs61411888, rs61295588, rs61282106, rs61250709, rs61235244,
rs61224243, rs61214927, rs61195471, rs61177390, rs61094188, rs61064130,
rs61046466, rs60992550, rs60934003, rs60890628, rs60872029, rs60864230,
rs60695352, rs60682848, rs60662302, rs60652225, rs60580541, rs60578328,

rs60556110, rs60458016, rs60446065, rs60310264, rs60290646, rs60168366,
 rs60029152, rs59981161, rs59931416, rs59914820, rs59885338, rs59684335,
 rs59653062, rs59601651, rs59564495, rs59332535, rs59301204, rs59270054,
 rs59267781, rs59065411, rs59040894, rs59026483, rs58978449, rs58932704,
 5 rs58922911, rs58917027, rs58912633, rs58850446, rs58789393, rs58727209,
 rs58672172, rs58571998, rs58541611, rs58436778, rs58389804, rs58362413,
 rs58327533, rs58133342, rs58105277, rs58100028, rs58048078, rs58034145,
 rs58013325, rs57983345, rs57966821, rs57920071, rs57883991, rs57877560,
 rs57830985, rs57793737, rs57747780, rs57730570, rs57629361, rs57520892,
 10 rs57394692, rs57318642, rs57207746, rs57077886, rs57048196, rs57045855,
 rs56984562, rs56935051, rs56851164, rs56816490, rs56793579, rs56771886,
 rs56699480, rs56694480, rs56673169, rs56657623, rs41269939, rs61742250,
 rs41264827, rs36059053, rs35507614, rs35396382, rs34777960, rs34704938,
 rs34626929, rs34195769, rs61726476, rs28933093, rs59963467, rs28933092,
 15 rs57128252, rs28933091, rs61675528, rs28933090, rs60789642, rs28928903,
 rs58312630, rs28928902, rs58044833, rs28928901, rs60711478, rs28928900,
 rs17856971, rs17847247, rs12562244, rs11581703, rs58224004, rs11575937,
 rs11549669, rs11549667, rs11549666, rs11542705, rs11539467, rs10920171,
 rs3209921, rs2501340, rs58367067, rs1779297, rs58820226, rs52796338, rs1626370,
 20 rs1043860, rs1043857, rs1043849, rs61070979, rs13768

Example 2. Identification of human remains using hair

Human remains are found for which DNA is not available due to the condition
 of the remains, as from prolonged environmental exposure and the discovery of
 25 partial remains. Since DNA is not present, but proteins present in the hard tissue of
 hair are available, hair samples from such remains are analyzed for polymorphisms.
 Investigatory samples are prepared and analyzed for polymorphisms as set forth in
 Examples 1A and 1B. At the same time known reference samples from potential
 individuals who are suspected to be the source of the remains (such as missing
 30 persons from the area where the remains were discovered) are similarly prepared and
 analyzed. Alternatively, samples from relatives of such persons (such as siblings or
 parents) are used as reference samples, particularly using SNPs from DNA samples
 from the prospective parents. Comparison of suitable peptide polymorphisms in the
 investigatory samples are compared to those of reference samples to exclude potential

identified individuals. For non-excluded individuals, data from comparative databases, such as those developed in accordance with Examples 1A through 1C, may be used to calculate the probability of a positive identification.

5 **Example 2A. Exclusion of potential criminal suspects using hair**

This technique of Example 2 is used to analyze human hair tissue found at a crime scene against known reference samples taken from known suspects. Comparison of suitable peptide polymorphisms against the reference samples is used to exclude potential suspects. For non-excluded individuals, data from comparative
10 databases, such as those developed in accordance with Examples 1A through 1C, may be used to calculate the probability of a positive identification.

Example 2B. Paternity exclusion testing using hair

This technique of Example 2 is used to analyze human hair tissue as part of
15 paternity testing. Hair samples from a child for which paternity is to be investigated are prepared and analyzed as set forth in Example 1A or 1B. At the same time known reference samples from potential individuals who are suspected to be the fathers of the child are similarly prepared and analyzed. Comparison of suitable peptide polymorphisms against the reference samples is used to exclude potential fathers. For
20 non-excluded individuals, data from comparative databases, such as those developed in accordance with Examples 1A through 1C, may be used to calculate the probability of a positive identification.

Example 3. Identification of human remains using skin, dentin, or bone

25 Human remains are found for which DNA is not available due to the condition of the remains, as from prolonged environmental exposure and the discovery of partial remains. Since DNA is not present, but proteins present in hard tissues of skin, dentin, and/or bone are available, a comparative databases of human skin, dentin, and/or bone proteins are developed by analyzing the ten most abundant proteins of
30 each for suitable polymorphisms to use as markers, using the UNIPROT database that contains a section of natural variation and provides the associated single nucleotide polymorphism (SNP), or other relevant literature or databases as known to those of skill in the art. The allelic frequency of each particular polymorphism is determined

relative to the reference sequence, and an approximate allelic frequency for the SNP that accounts for the amino acid polymorphism is calculated.

5 Samples of skin, dentin, and/or bone from such remains are analyzed for polymorphisms. Investigatory samples are prepared and analyzed for polymorphisms using a protocol similar to those set forth in Examples 1A and 1B. At the same time
10 known reference samples from potential individuals who are suspected to be the source of the remains (such as missing persons from the area where the remains were discovered) are similarly prepared and analyzed. Alternatively, samples from relatives of such persons (such as siblings or parents) are used as reference samples. Comparison of suitable peptide polymorphisms in the investigatory samples are
15 compared to those of the reference samples to exclude potential identified individuals. For non-excluded individuals, data from the comparative database may be used to calculate probabilities of a positive identification.

Example 4. Determination of relationships for historic human remains

Investigatory hair samples from human remains for a historical group, such as those in archeological or anthropological collections, for which DNA is not available due to the condition of the remains, as from prolonged environmental exposure or otherwise, but for which proteins present in the hard tissue of hair are available, are
20 analyzed for polymorphisms as set forth in Example 2. At the same time known reference samples from present day population groups, or other historical groups, are similarly prepared and analyzed. Comparison of suitable peptide polymorphisms in the investigatory samples are compared to those of the reference samples. Data from comparative databases, such as those developed in accordance with Examples 1A through 1C, may be used to calculate the likely statistics between the groups to
25 examine possible phylogenetic relationships for the study of historical relationships between historic populations and development of modern populations. For example the genetic distance from given genetic populations, such as a sub-Saharan population, can be calculated.

30

Example 5. Identification of non-human remains using hair

Non-human remains are found for which DNA is not available due to the condition of the remains. For example, customs agents find a shipment of products made using the tissues of an endangered species that include hair. Hair samples from

such products are analyzed for protein polymorphisms, using a protocol similar to those set forth in Examples 1A and 1B. By comparison of suitable peptide polymorphisms from samples of individual products, it can be determined if the products were prepared from more than one individual of the endangered species. Where reference data is available, as by the development of a comparative database as explained previously herein, data from the comparative database may be used to calculate the source of the remains, as by genetic distance to known population groups for the endangered species.

Example 6. Identification of non-human remains using hair

It is often very difficult to obtain usable DNA from a perpetrator in rape kits. This is because the victim's DNA occurs at a much greater percentage than the perpetrators DNA. Some success is achieved through specifically amplifying markers on the male-specific Y-Chromosome. Unfortunately this is patrilineal and has limited genetic power. This sometimes makes it difficult to provide enough probative information to convict. However, genetic polymorphic markers also occur on proteins. Therefore male specific proteins in semen, when detected in a rape kit sample, have the potential to provide genetic information that is autosomal and non-redundant with Y-chromosome specific markers. This will expand the forensically probative information from rape kits.

Male specific proteins from a rape kit sample are analyzed for protein polymorphisms as investigatory samples, using a protocol similar to those set forth in Examples 1A and 1B. At the same time known reference samples from potential individuals who are suspected to be the source of the rape kit sample are similarly prepared and analyzed. Alternatively, samples from relatives of such persons (such as siblings or parents) are used as reference samples. Comparison of suitable peptide polymorphisms in the investigatory samples are compared to those of the reference samples to exclude potential identified individuals. For non-excluded individuals, Random Match probabilities may be calculation using data from a comparative database to calculate probabilities of a positive identification.

While this invention has been described in certain embodiments, the present invention can be further modified within the spirit and scope of this disclosure. This application is therefore intended to cover any variations, uses, or adaptations of the invention using its general principles. Further, this application is intended to cover

such departures from the present disclosure as come within known or customary practice in the art to which this invention pertains and which fall within the limits of the appended claims.

All references, including publications, patents, and patent applications, cited herein are hereby incorporated by reference to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein.

Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.

The reference in this specification to any prior publication (or information derived from it), or to any matter which is known, is not, and should not be taken as an acknowledgment or admission or any form of suggestion that that prior publication (or information derived from it) or known matter forms part of the common general knowledge in the field of endeavour to which this specification relates.

2011229918 22 Sep 2014

The claims defining the invention are as follows:

1. A method of using protein polymorphism biomarkers to conduct genetic analysis on a proteinaceous tissue sample, the method comprising:
 - extracting a mixture of proteins from the proteinaceous tissue sample;
 - digesting the extracted mixture of proteins with trypsin;
 - identifying a pattern of polymorphic tryptic peptides present within the extracted mixture of proteins; and
 - analyzing the identified polymorphic tryptic peptides present within the extracted mixture of proteins to make a determination as to a genetic relationship of a source of the proteinaceous tissue sample.
2. The method according to claim 1, wherein identifying polymorphic tryptic peptides present within the extracted mixture of proteins comprises using mass spectrometry to determine the peptide residues present in the extracted mixture of proteins.
3. The method according to claim 2, wherein using mass spectrometry to determine the peptide residues present in the extracted mixture of proteins comprises resolving digested extracted protein with reversed-phase liquid chromatography followed by mass spectrometry to fragment individual peptide backbones within the digested extracted mixture of proteins and then measure the resulting pieces to obtain a distinctive pattern corresponding to the individual peptides present.
4. The method according to claim 1, wherein identifying polymorphic tryptic peptides present within the extracted mixture of proteins comprises identifying polymorphic peptides corresponding to known polymorphic variants of proteins present in the proteinaceous tissue sample that correspond to single nucleotide polymorphisms.
5. The method according to claim 4, wherein identifying polymorphic peptides corresponding to known polymorphic variants of proteins present in the proteinaceous tissue that correspond to single nucleotide protein polymorphisms comprises identifying polymorphic peptides corresponding to single nucleotide protein polymorphic variants

selected from the group consisting of desmoplakin; keratin, type I cuticular Ha2; plakophilin-1; stratifin; keratin, type I cytoskeletal 39; protein-glutamine gamma-glutamyltransferase; keratin, type II cuticular Hb1 ; keratin, type II cuticular Hb3; keratin, type II cuticular Hb5; keratin, type II cuticular Hb6; bleomycin hydrolase; L-lactate dehydrogenase A chain; keratin, type I cuticular Hb2; keratin, type I cuticular Ha3-II; selenium-binding protein 1; 14-3-3 protein sigma; desmoglein-4; ATP synthase subunit alpha, mitochondrial; annexin A2; bleomycin hydrolase; and leucine-rich repeat-containing protein 15.

6. The method according to claim 4, wherein identifying polymorphic peptides corresponding to known polymorphic variants of proteins present in the proteinaceous tissue sample that correspond to single nucleotide polymorphisms comprises identifying polymorphic peptides corresponding to known single nucleotide polymorphisms that are missense mutations.

7. The method of claim 4, wherein analyzing the identified polymorphic tryptic peptides present within the extracted mixture of proteins to make a determination as to a genetic relationship of a source of the proteinaceous tissue sample comprises comparing the presence of the individual protein polymorphism biomarkers identified from the polymorphic tryptic peptides to reference protein polymorphism biomarkers in a database to conduct genetic analysis.

8. The method of claim 7, wherein the genetic analysis comprises calculation of a probability that the proteinaceous tissue sample originated with a particular individual, or calculation of a genetic distance between the tissue sample and a known genetic population.

9. The method of claim 7, wherein the genetic analysis comprises exclusion of potential individuals, identification of a specific individual, or an identification of paternity.

10. The method of claim 7, wherein the genetic analysis comprises calculation of a

Random Match Probability.

11. The method according to claim 1, wherein identifying polymorphic tryptic peptides present within the extracted mixture of proteins comprises identifying polymorphic peptides corresponding to male specific trypsin-digested peptides in the Y-chromosome isoform of amelogenin.

12. The method of any one of claims 1 to 11, wherein the proteinaceous tissue sample comprises human hair, bone or tooth tissue.

13. A process for conducting genetic analysis on a hair sample, comprising:
extracting a mixture of proteins from the hair sample;
digesting the extracted mixture of proteins with trypsin;
identifying a pattern of tryptic peptides present within the extracted mixture of proteins; and
analyzing the identified pattern of tryptic peptides present within the extracted mixture of proteins to identify protein polymorphisms of interest to make a determination as to a genetic relationship of a source of the hair sample.

14. The process according to claim 13, wherein identifying tryptic peptides present within the extracted mixture of proteins comprises using mass spectrometry to determine the peptide residues present in the extracted protein.

15. The process according to claim 14, wherein using mass spectrometry to determine the peptide residues present in the extracted mixture of proteins comprises resolving digested extracted protein with reversed-phase liquid chromatography followed by mass spectrometry to fragment individual peptide backbones within the digested extracted mixture of proteins and then measuring the resulting pieces to obtain a distinctive pattern corresponding to the individual peptides present.

16. The process according to claim 13, wherein analyzing the identified pattern of tryptic peptides present within the extracted mixture of proteins to identify protein

polymorphisms of interest to make a determination as to a genetic relationship of a source of the hair sample comprises identifying polymorphic peptides corresponding to known polymorphic variants of proteins present in hair tissue that correspond to single nucleotide protein polymorphisms.

17. The process according to claim 16, wherein identifying polymorphic peptides corresponding to known polymorphic variants of proteins present in hair tissue that correspond to single nucleotide protein polymorphisms comprises identifying polymorphic peptides corresponding to single nucleotide protein polymorphic variants selected from the group consisting of at least one of desmoplakin; keratin, type I cuticular Ha2; plakophilin-1; stratifin; keratin, type I cytoskeletal 39; protein-glutamine gamma-glutamyltransferase; keratin, type II cuticular Hb1; keratin, type II cuticular Hb3; keratin, type II cuticular Hb5; keratin, type II cuticular Hb6; bleomycin hydrolase; L-lactate dehydrogenase A chain; keratin, type I cuticular Hb2; keratin, type I cuticular Ha3-II; selenium-binding protein 1; 14-3-3 protein sigma; desmoglein-4; ATP synthase subunit alpha, mitochondrial; annexin A2; bleomycin hydrolase ; and leucine-rich repeat-containing protein 15.

18. The process according to claim 16, wherein analyzing the identified pattern of tryptic peptides present within the extracted mixture of proteins to identify protein polymorphisms of interest to make a determination as to a genetic relationship of a source of the hair sample further comprises comparing the presence of identified single nucleotide protein polymorphisms within the hair sample to reference protein polymorphism biomarkers in a database to conduct genetic analysis.

19. The process of claim 18, wherein making a determination as to a genetic relationship of a source of the hair sample further comprises calculation of a probability that the hair sample originated with a particular individual, or calculation of a genetic distance between the source of the hair sample and a known genetic population.

20. The process of claim 18, wherein making a determination as to a genetic relationship of a source of the hair sample comprises exclusion of potential individuals, identification of a specific individual, or an identification of paternity.

21. The process of claim 18, wherein the making a determination as to a genetic relationship of a source of the hair sample comprises calculation of a Random Match Probability

22. The process according to claim 13, wherein digesting the extracted mixture of proteins with trypsin comprises digestion in the presence of a protease enhancer.

23. A method as claimed in claim 1, and substantially as herein described with reference to the examples.

2011229918 05 Dec 2014

	peptide	mass	allelic frequency
Desmoplakin			
	<i>NTNIAQK</i> SEQ ID NO: 125	787.418	0.78
I305F	<i>NTNFAQK</i> SEQ ID NO: 126	821.403	0.22
	<i>VQYDLQK</i> SEQ ID NO: 127	892.465	0.79
Y1512C	<i>VQCCLQK</i> SEQ ID NO: 128	832.411	0.21
Keratin, type II cuticular Hb2			
	<i>PCVENEFVALK</i> SEQ ID NO: 129	1247.622	0.99
E219Q	<i>PCVQNEFVALK</i> SEQ ID NO: 130	1246.637	0.01
	<i>GAFLYEPCGVSTPVLSTGVLR</i> SEQ ID NO: 131	2165.119	0.04
E452D	<i>GAFLYIDPCGVSTPVLSTGVLR</i> SEQ ID NO: 132	2151.103	0.68
M458T	<i>GAFLYIDPCGVSMIPVLSTGVLR</i> SEQ ID NO: 133	2181.096	0.27
Keratin, type I cuticular Ha2			
	<i>MVVNIDNAK</i> SEQ ID NO: 74	1002.516	0.93
I171T	<i>MVVNTDNAK</i> SEQ ID NO: 75	990.48	0.05
	<i>ADLEAQVESLK</i> SEQ ID NO: 134	1201.619	0.46
S222Y	<i>ADLEAQVEYLK</i> SEQ ID NO: 135	1277.65	0.54
	<i>DSLENTLTFESEAR</i> SEQ ID NO: 58	1463.673	0.99
T339M	<i>DSLENMLTFESEAR</i> SEQ ID NO: 59	1493.666	0.01
	<i>LEGFINTYR</i> SEQ ID NO: 3	1093.54	0.63
T395M	<i>LEGEINMYR</i> SEQ ID NO: 4	1123.533	0.37
	<i>LPCNPCSTPSCTTCVPSPCVTR</i> SEQ ID NO: 136	2264.972	0.19
T427P	<i>LPCNPCSTPSCTTCVPSPCVPR</i> SEQ ID NO: 137	2260.977	0.78
	<i>LPCNPCSTPSCTTCVPSPCVTR</i> SEQ ID NO: 136	2264.972	0.79
R428C	<i>LPCNPCSTPSCTTCVPSPCVTCTVCVPR</i> SEQ ID NO: 138	2867.227	0.05

Keratin, type II cuticular Hb2
 KRT32_HUMAN
 Q9NDB4
 E452D rs1732263 VAR_032786
 M458I rs2658558 VAR_032787
 E219Q rs1791634 VAR_018118

Desmoplakin
 DESP_HUMAN
 P15924
 I305F rs17604693 VAR_033862
 Y1512C rs2076299 VAR_020488
 R1739Q rs34738426 VSP_005070
 rs28931610 VAR_015569
 VAR_015402
 VAR_023614
 VAR_023616
 VAR_015570
 VAR_016158

Keratin, type I cuticular Ha2
 K1H2_HUMAN
 Q14532
 Q72R rs3744786 VAR_056011
 D151E rs1111168 VAR_060237
 I171T rs2071560 VAR_056012
 T573C rs2071560 VAR_056013
 C725A rs2071561 VAR_060238
 C1077T rs1896929 VAR_056014
 C1245T rs2071563 VAR_056015
 A1266G rs2604955 VAR_060239
 C1340A rs2604953 VAR_060240
 C1343T rs9893787 VAR_056016

Selenium binding protein 1
 SBP1_HUMAN
 Q13220
 I122V rs35396382
 F135C rs1043557
 A384T rs1043360
 E367K rs7271012
 A262T rs11581703

Plakophilin-1
 PKP1_HUMAN
 Q13835
 I12X432 VSP_006735
 R115H rs34626929 VAR_033526
 C161Y rs34704938 VAR_033527
 I196V rs33507614 VAR_043528
 G415D rs1626370 VAR_053611
 A463V rs1092917 VAR_062171

Junction plakoglobin
 PLAK_HUMAN
 S3955
 M697L rs1126821 VAR_037603
 VAR_037604

Desmoglein-4
 DSG4_HUMAN
 Q86516
 G92a1711 VSP_012907
 I25K335 VAR_021291
 A154T rs13381457 VAR_048514
 I535T rs7229252 VAR_033700
 I644L rs4799370 VAR_024207

Stratifin
 I4335_HUMAN
 P31947
 85K116 VSP_021768
 M155I rs11542705 VAR_048095

Keratin-associated protein 11-1
 KR111_HUMAN
 Q81UC1
 C1115 rs9636845 VAR_053467

Keratin, type II cuticular Hb5
 KRT35_HUMAN
 P73385
 R78H rs61633004 VAR_029657
 W155L rs2652471 VAR_049804

Keratin, type I cytoskeletal 39
 K1C39_HUMAN
 Q6A153
 T341M rs17843021 VAR_038075
 L383M rs17843023 VAR_038076
 R455Q rs7213256 VAR_036077

Keratin, type I cuticular Ha5
 KRT35_HUMAN
 Q92754
 S36P rs743636 VAR_056019
 C114Y rs12451652 VAR_056020
 P443A rs2071501 VAR_056021

Actin, cytoplasmic 1
 ACTB_HUMAN
 P63709
 R183W rs11545899 VAR_030026
 P743I rs11545899 VAR_048185

Keratin, type I cuticular Ha4
 KRT34_HUMAN
 Q76011
 I260T rs2239710 VAR_056017
 H348R rs2071500 VAR_056018

Keratin, type II cuticular Hb6
 KRT36_HUMAN
 O43790
 N114D VAR_018125
 N114H VAR_023053
 E402K VAR_018127
 E402Q rs28939669 VAR_018126
 E413D VAR_018129
 E413K VAR_018128

Keratin, type II cuticular Hb1
 KRT31_HUMAN
 Q14533
 G52R rs2071588 VAR_018113
 R248L rs6580873 VAR_018114
 R315C rs4761786 VAR_018115
 E402K VAR_018116
 E413K rs57419521 VAR_018117

Keratin, type II cuticular Hb3
 KRT33_HUMAN
 P73385
 R149C rs2657563 VAR_018119
 I279M rs2652464 VAR_018120
 E407K VAR_023052
 H493Y rs2857571 VAR_018121

Keratin, type I cuticular Ha1
 K1H1_HUMAN
 Q15323
 A39G rs6503528 VAR_046989
 A82V rs6503527 VAR_046990
 A377Y rs34293483 VAR_046991

Keratin, type I cuticular Ha3-I
 KT33A_HUMAN
 O76039
 A279V rs12937519 VAR_054432

Keratin, type I cuticular Ha3-II
 KT33B_HUMAN
 Q14525

Protein-glutamine gamma-glutamyltransferase E
 TGM3_HUMAN
 Q08188
 T13K rs214803 VAR_040067
 I163L rs6048066 VAR_040068
 S249N rs214814 VAR_040069
 K562R rs1042517 VAR_040070
 G654A rs1042517 VAR_040071
 L687M rs45581032 VAR_055360

Keratin, type II cytoskeletal 1
 K2C1_HUMAN
 P04264

K74I rs57977969 VAR_017819
 V155D rs1042517 VAR_017820
 V155G rs57953072 VAR_003853
 L151P rs57695159 VAR_003854
 I75K197 rs60022878 VAR_003855
 S188P rs55479455 VAR_017821
 N188S rs58928370 VAR_003856
 N180T VAR_017822
 S193P rs60937700 VAR_003857
 L214P rs61549035 VAR_017823
 I312V VAR_003858
 I330T VAR_003859
 D340V rs58062863 VAR_017824
 Y358N rs1050372 VAR_003860
 A454S rs17673945 VAR_038628
 I59K166 VAR_038629
 I479F rs61718439 VAR_017825
 I479T rs57837128 VAR_017826
 Y482C rs58420087 VAR_017827
 L486P rs56914602 VAR_017828
 E490Q rs60279707 VAR_003861
 G537C VAR_003862
 S60X566 VAR_003864
 K633R rs14024 VAR_003863

Fatty acid-binding protein, adipocyte
 FABP4_HUMAN
 P15090
 E23D VAR_036320

Calmodulin-like protein 3
 CAL3_HUMAN
 P27482

```

MCTNLLPACLLCAAPAMDLPPDNDCHDQVINEPVEE          VLFDLHWYQE I 45
MCTNLLPACLVCAAPAMDLPPDNDCHDQVINEPVEESHSSQAINVDH ITALYLTPLRHWYQSKI 60
*****
RFDYPSYCTEPNCGNLEHQEIPVLSQQHDFYHTLQPHSHIPVVVPAQQPVIPQQDHPVPG 105
RFDYSSYCTEPNCGNLEHQEIPVVVSOQHDLFHTLQSHSHIPVVVPAQQPVVQQALNPVPG 120
*****
QHSMTPTQHHQDNLPLPFAQQPVPQPVCTQPHQDHPQPPVVPVHQPLPQPPLDPMFDMQ 165
QHSMTPTQHHQDNLPLPFAQQPVPQPVCTQPHQDHPQPPVVPVHQPLPQPPLDPMFPLR 180
*****
FLDPHLPLDLEAWDSTQKTEREEVD 191 AMEIX_HUMAN SEQ ID NO:
FLDPHLPLDLEAWDSTQKTEREEVD 206 AMEIX_HUMAN SEQ ID NO:
*****

```

SEQUENCE LISTING

<110> Parker, Glendon J

5 <120> METHODS FOR CONDUCTING GENETIC ANALYSIS
USING PROTEIN
 POLYMORPHISMS

10 <130> 4766.GPAR.NP

 <150> US 60/340,918

 <151> 2010-03-24

15 <160> 140

 <170> PatentIn version 3.5

 <210> 1

 <211> 7

20 <212> PRT

 <213> Homo sapiens

 <400> 1

25 Ser Glu Ala Asp Ser Asp Lys
 1 5

30 <210> 2

 <211> 9

 <212> PRT

 <213> Homo sapiens

 <400> 2

Gly Gln Ser Glu Ala Asp Ser Asp Lys

1 5

5

<210> 3

<211> 9

<212> PRT

<213> Homo sapiens

10

<400> 3

Leu Glu Gly Glu Ile Asn Thr Tyr Arg

1 5

15

<210> 4

<211> 9

<212> PRT

20

<213> Homo sapiens

<400> 4

Leu Glu Gly Glu Ile Asn Met Tyr Arg

1 5

25

<210> 5

<211> 12

<212> PRT

30

<213> Homo sapiens

<400> 5

Phe Ser Ser Tyr Ser Gln Met Glu Asn Trp Ser Arg

1 5 10

5

<210> 6

<211> 13

<212> PRT

<213> Homo sapiens

10

<400> 6

His Phe Ser Ser Tyr Ser Gln Met Glu Asn Trp Ser Arg

1 5 10

15

<210> 7

<211> 11

<212> PRT

<213> Homo sapiens

20

<400> 7

Ser Ala Tyr Gln Glu Ala Met Asp Ile Ser Lys

1 5 10

25

<210> 8

<211> 11

<212> PRT

30

<213> Homo sapiens

<400> 8

Ser Ala Tyr Gln Glu Ala Ile Asp Ile Ser Lys

1 5 10

<210> 9

5

<211> 12

<212> PRT

<213> Homo sapiens

<400> 9

10

Gln Asn Gln Glu Tyr Glu Ile Leu Leu Asp Val Lys

1 5 10

15

<210> 10

<211> 12

<212> PRT

<213> Homo sapiens

20

<400> 10

Gln Asn Gln Glu Tyr Glu Ile Leu Met Asp Val Lys

1 5 10

25

<210> 11

<211> 10

<212> PRT

<213> Homo sapiens

30

<400> 11

Ser Trp Asn Gly Ser Val Glu Ile Leu Lys

1 5 10

<210> 12

<211> 10

5

<212> PRT

<213> Homo sapiens

<400> 12

10

Asn Trp Asn Gly Ser Val Glu Ile Leu Lys

1 5 10

<210> 13

15

<211> 12

<212> PRT

<213> Homo sapiens

<400> 13

20

Asp Leu Asn Met Asp Cys Ile Val Ala Glu Ile Lys

1 5 10

25

<210> 14

<211> 12

<212> PRT

<213> Homo sapiens

30

<400> 14

Asp Leu Asn Met Asp Cys Met Val Ala Glu Ile Lys

1 5 10

<210> 15

<211> 27

<212> PRT

5 <213> Homo sapiens

<400> 15

His Val Pro Glu Glu Val Leu Ala Val Leu Glu Gln Glu Pro Ile Ile

10 1 5 10 15

Leu Pro Ala Trp Asp Pro Met Gly Ala Leu Ala

15 20 25

<210> 16

<211> 27

<212> PRT

20 <213> Homo sapiens

<400> 16

His Val Pro Glu Glu Val Leu Ala Val Leu Glu Gln Glu Pro Ile Val

25 1 5 10 15

Leu Pro Ala Trp Asp Pro Met Gly Ala Leu Ala

30 20 25

<210> 17

<211> 12

<212> PRT

<213> Homo sapiens

<400> 17

5 Val Ile Gly Ser Gly Cys Asn Leu Asp Ser Ala Arg

1 5 10

<210> 18

10

<211> 8

<212> PRT

<213> Homo sapiens

<400> 18

15

Gly Cys Asn Leu Asp Ser Ala Arg

1 5

20

<210> 19

<211> 9

<212> PRT

<213> Homo sapiens

25

<400> 19

Asn Leu His Ser Glu Ile Ser Gly Lys

1 5

30

<210> 20

<211> 9

<212> PRT

<213> Homo sapiens

<400> 20

Asn Leu His Ser Glu Ile Ser Ser Lys

5 1 5

<210> 21

<211> 10

10 <212> PRT

<213> Homo sapiens

<400> 21

15 Thr Thr Ile His Gln Leu Thr Met Gln Lys

1 5 10

<210> 22

20 <211> 18

<212> PRT

<213> Homo sapiens

<400> 22

25 Thr Thr Ile His Gln Leu Thr Met Gln Lys Glu Glu Asp Thr Ser Gly

1 5 10 15

30 Tyr Arg

<210> 23

<211> 10

<212> PRT

<213> Homo sapiens

5

<400> 23

Thr Thr Ile His Gln Leu Ser Met Gln Lys

1 5 10

10

<210> 24

<211> 11

<212> PRT

<213> Homo sapiens

15

<400> 24

Ala Asn Ser Ser Ala Thr Glu Thr Ile Asn Lys

1 5 10

20

<210> 25

<211> 11

<212> PRT

25

<213> Homo sapiens

<400> 25

Ala Asn Ser Ser Ala Thr Glu Thr Ile Lys Lys

1 5 10

30

<210> 26

<211> 10

<212> PRT

<213> Homo sapiens

<400> 26

5

Val Gln Glu Gln Glu Leu Thr Arg Leu Arg

1 5 10

10

<210> 27

<211> 10

<212> PRT

<213> Homo sapiens

15

<400> 27

Val Gln Glu Gln Glu Leu Thr Cys Leu Arg

1 5 10

20

<210> 28

<211> 15

<212> PRT

<213> Homo sapiens

25

<400> 28

Ser Glu Ala Asp Ser Asp Lys Asn Ala Thr Ile Leu Glu Leu Arg

1 5 10 15

30

<210> 29

<211> 16

<212> PRT

<213> Homo sapiens

<400> 29

5 Leu Glu Tyr Asp Leu Arg Arg Gly Gln Ser Glu Ala Asp Ser Asp Lys
1 5 10 15

<210> 30

10 <211> 9

<212> PRT

<213> Homo sapiens

<400> 30

15 Ile Ser Ile Thr Glu Gly Ile Glu Arg
1 5

20 <210> 31

<211> 19

<212> PRT

<213> Homo sapiens

25 <400> 31

Ile Ser Ile Thr Glu Gly Ile Glu Gln Leu Ile Val Asp Ser Ile Thr
1 5 10 15

30 Gly Gln Arg

<210> 32
<211> 7
<212> PRT
<213> Homo sapiens

5

<400> 32

Leu Tyr Glu Glu Glu Ile Arg

1 5

10

<210> 33
<211> 8
<212> PRT
<213> Homo sapiens

15

<400> 33

Trp Leu Tyr Glu Glu Glu Ile Arg

1 5

20

<210> 34
<211> 13
<212> PRT
<213> Homo sapiens

25

<400> 34

Val Leu Gln Ser His Ile Ser Asp Thr Val Val Val Lys

1 5 10

30

<210> 35

<211> 13
<212> PRT
<213> Homo sapiens

5 <400> 35

Ile Leu Gln Ser His Ile Ser Asp Thr Val Val Val Lys
1 5 10

10

<210> 36
<211> 11
<212> PRT
<213> Homo sapiens

15

<400> 36

Glu Ala Glu Cys Val Glu Ala Asp Ser Gly Arg
1 5 10

20

<210> 37
<211> 11
<212> PRT
<213> Homo sapiens

25

<400> 37

Glu Ala Glu Cys Val Glu Ala Asn Ser Gly Arg
1 5 10

30

<210> 38
<211> 8

<212> PRT

<213> Homo sapiens

<400> 38

5

Asp Val Asp Cys Ala Tyr Leu Arg

1 5

10

<210> 39

<211> 8

<212> PRT

<213> Homo sapiens

15

<400> 39

Asp Val Asp Gly Ala Tyr Leu Arg

1 5

20

<210> 40

<211> 10

<212> PRT

<213> Homo sapiens

25

<400> 40

Ser Ser Ser Phe Ser Cys Gly Ser Ser Arg

1 5 10

30

<210> 41

<211> 37

<212> PRT

<213> Homo sapiens

<400> 41

5 Gln Ile Thr Ser Gly Pro Ser Ala Ile Gly Gly Ser Ile Thr Val Val
1 5 10 15

10 Ala Pro Asp Ser Cys Ala Pro Cys Gln Pro Leu Ser Ser Ser Phe Ser
20 25 30

Cys Gly Ser Ser Arg
35

15

<210> 42

<211> 21

<212> PRT

20 <213> Homo sapiens

<400> 42

25 Leu Tyr Glu Glu Glu Ile Leu Ile Leu Gln Ser His Ile Ser Asp Thr
1 5 10 15

Ser Val Val Val Lys
20

30

<210> 43

<211> 7

<212> PRT

<213> Homo sapiens

<400> 43

5 Leu Tyr Glu Glu Glu Ile Arg

1 5

<210> 44

10 <211> 14

<212> PRT

<213> Homo sapiens

<400> 44

15 Ile Leu Gln Ser His Ile Ser Asp Thr Ser Val Val Val Lys

1 5 10

20 <210> 45

<211> 6

<212> PRT

<213> Homo sapiens

25 <400> 45

His Gly Glu Thr Leu Arg

1 5

30

<210> 46

<211> 7

<212> PRT

<213> Homo sapiens

<400> 46

His Gly Glu Thr Leu Cys Arg

5 1 5

<210> 47

<211> 16

10 <212> PRT

<213> Homo sapiens

<400> 47

15 Gly Leu Thr Gly Gly Phe Gly Ser His Ser Val Cys Gly Gly Phe Arg

1 5 10 15

<210> 48

20 <211> 14

<212> PRT

<213> Homo sapiens

<400> 48

25 Gly Leu Thr Gly Gly Phe Gly Ser His Ser Val Cys Gly Arg

1 5 10

30 <210> 49

<211> 8

<212> PRT

<213> Homo sapiens

<400> 49

Leu Leu Glu Gly Glu Glu Gln Arg

1 5

5

<210> 50

<211> 8

<212> PRT

10

<213> Homo sapiens

<400> 50

Leu Leu Glu Gly Lys Glu Glu Arg

1 5

15

<210> 51

<211> 10

20

<212> PRT

<213> Homo sapiens

<400> 51

25

Asp Asn Ala Glu Leu Glu Asn Leu Ile Arg

1 5 10

30

<210> 52

<211> 10

<212> PRT

<213> Homo sapiens

<400> 52

Asp Asn Ala Glu Leu Lys Asn Leu Ile Arg

1 5 10

5

<210> 53

<211> 21

<212> PRT

<213> Homo sapiens

10

<400> 53

Leu Asn Val Glu Val Asp Ala Ala Pro Ala Val Asp Leu Asn Gln Val

1 5 10 15

15

Leu Asn Glu Thr Arg

20

20

<210> 54

<211> 21

<212> PRT

<213> Homo sapiens

25

<400> 54

Leu Asn Val Glu Val Asp Ala Ala Pro Ala Val Asp Leu Asn Arg Val

1 5 10 15

30

Leu Asn Glu Thr Arg

20

<210> 55

<211> 20

<212> PRT

5 <213> Homo sapiens

<400> 55

Gln Val Val Ser Ser Ser Glu Gln Leu Gln Ser Tyr Gln Ala Glu Ile

10 1 5 10 15

Ile Glu Leu Arg

20

15

<210> 56

<211> 20

<212> PRT

20 <213> Homo sapiens

<400> 56

Gln Val Val Ser Ser Ser Glu Gln Leu Gln Ser Tyr Gln Val Glu Ile

25 1 5 10 15

Ile Glu Leu Arg

20

30

<210> 57

<211> 16

<212> PRT

<213> Homo sapiens

<400> 57

5 Thr Val Asn Ala Leu Glu Ile Glu Leu Gln Ala Gln His Asn Leu Arg
1 5 10 15

<210> 58

10 <211> 16

<212> PRT

<213> Homo sapiens

<400> 58

15 Thr Leu Asn Ala Leu Glu Ile Glu Leu Gln Ala Gln His Asn Leu Arg
1 5 10 15

20 <210> 59

<211> 13

<212> PRT

<213> Homo sapiens

25 <400> 59

Tyr Ser Leu Glu Asn Thr Leu Thr Glu Ser Glu Ala Arg
1 5 10

30

<210> 60

<211> 13

<212> PRT

<213> Homo sapiens

<400> 60

Asp Ser Leu Glu Asn Thr Leu Thr Glu Ser Glu Ala Arg

5 1 5 10

<210> 61

<211> 23

10 <212> PRT

<213> Homo sapiens

<400> 61

15 Tyr Ser Ser Gln Leu Ser Gln Val Gln Ser Leu Ile Thr Asn Val Glu

1 5 10 15

Ser Gln Leu Ala Glu Ile Arg

20 20

<210> 62

<211> 28

25 <212> PRT

<213> Homo sapiens

<400> 62

30 Tyr Ser Ser Gln Leu Ser Gln Val Gln Ser Leu Ile Thr Asn Val Glu

1 5 10 15

Ser Gln Leu Ala Glu Ile His Ser Asp Leu Glu Arg

20 25

5

<210> 63
<211> 13
<212> PRT
<213> Homo sapiens

10

<400> 63

Gly Gly Pro Val Gln Val Leu Glu Asp Glu Glu Leu Lys
1 5 10

15

<210> 64
<211> 10
<212> PRT
<213> Homo sapiens

20

<400> 64

Gly Gly Pro Val Gln Val Leu Glu Asp Lys
1 5 10

25

<210> 65
<211> 12
<212> PRT
<213> Homo sapiens

30

<400> 65

Glu Leu Asp Val Asp Gly Ile Ile Ala Glu Ile Lys
1 5 10

5 <210> 66
<211> 12
<212> PRT
<213> Homo sapiens

<400> 66

10 Glu Leu Asp Val Asp Ser Ile Ile Ala Glu Ile Lys
1 5 10

15 <210> 67
<211> 8
<212> PRT
<213> Homo sapiens

<400> 67

20 Asn Glu Ile Leu Glu Met Asn Lys
1 5

25 <210> 68
<211> 8
<212> PRT
<213> Homo sapiens

30 <400> 68

Lys Glu Ile Leu Glu Met Asn Lys
1 5

<210> 69

<211> 9

<212> PRT

5 <213> Homo sapiens

<400> 69

Glu Thr Met Gln Phe Leu Asn Asp Arg

10 1 5

<210> 70

<211> 9

<212> PRT

15 <213> Homo sapiens

<400> 70

Glu Ile Met Gln Phe Leu Asn Asp Arg

20 1 5

<210> 71

<211> 8

<212> PRT

25 <213> Homo sapiens

<400> 71

Thr Ile Glu Glu Leu Gln Gln Lys

30 1 5

<210> 72
<211> 8
<212> PRT
<213> Homo sapiens

5

<400> 72

Thr Ile Asp Glu Leu Gln Gln Lys

1 5

10

<210> 73
<211> 8
<212> PRT
<213> Homo sapiens

15

<400> 73

Thr Ile Glu Gln Leu Gln Gln Lys

1 5

20

<210> 74
<211> 9
<212> PRT
<213> Homo sapiens

25

<400> 74

Met Val Val Asn Ile Asp Asn Ala Lys

1 5

30

<210> 75

<211> 9
<212> PRT
<213> Homo sapiens

5 <400> 75

Met Val Val Asn Thr Asp Asn Ala Lys
1 5

10

<210> 76
<211> 16
<212> PRT
<213> Homo sapiens

15

<400> 76

Thr Val Asn Thr Leu Glu Ile Glu Leu Gln Ala Gln His Ser Leu Arg
1 5 10 15

20

<210> 77
<211> 17
<212> PRT
<213> Homo sapiens

25

<400> 77

Cys Thr Val Asn Thr Leu Glu Ile Glu Leu Gln Ala Gln His Ser Leu
1 5 10 15

30

Arg

5 <210> 78
<211> 13
<212> PRT
<213> Homo sapiens

<400> 78

10 Asp Ser Leu Glu Asn Thr Leu Thr Glu Ser Glu Ala Arg
1 5 10

<210> 79
15 <211> 13
<212> PRT
<213> Homo sapiens

<400> 79
20 Asp Ser Leu Glu Asn Met Leu Thr Glu Ser Glu Ala Arg
1 5 10

25 <210> 80
<211> 23
<212> PRT
<213> Homo sapiens

30 <400> 80

Tyr Ser Ser Gln Leu Ala Gln Met Gln Cys Met Ile Thr Asn Val Glu
1 5 10 15

Ala Gln Leu Ala Glu Ile Arg

20

5

<210> 81

<211> 28

<212> PRT

<213> Homo sapiens

10

<400> 81

Tyr Ser Ser Gln Leu Ala Gln Met Gln Cys Met Ile Thr Asn Val Glu

1 5 10 15

15

Ala Gln Leu Ala Glu Ile Gln Ala Asp Leu Glu Arg

20 25

20

<210> 82

<211> 5

<212> PRT

<213> Homo sapiens

25

<400> 82

Ala Asp Leu Glu Arg

1 5

30

<210> 83

<211> 5

<212> PRT

<213> Homo sapiens

<400> 83

5 Ala Glu Leu Glu Arg
1 5

<210> 84

10 <211> 18

<212> PRT

<213> Homo sapiens

<400> 84

15 Ala Glu Leu Glu Arg Gln Asn Gln Glu Tyr Gln Val Leu Leu Asp Asp
1 5 10 15

20 Val Arg

<210> 85

25 <211> 11

<212> PRT

<213> Homo sapiens

<400> 85

30 Ala Arg Leu Glu Gly Glu Ile Asn Thr Tyr Arg
1 5 10

<210> 86
<211> 9
<212> PRT
<213> Homo sapiens

5

<400> 86

Ser Leu Leu Glu Asn Glu Asp Cys Lys

1 5

10

<210> 87
<211> 9
<212> PRT
<213> Homo sapiens

15

<400> 87

Ser Leu Leu Glu Ser Glu Asp Cys Lys

1 5

20

<210> 88
<211> 11
<212> PRT
<213> Homo sapiens

25

<400> 88

Ser Ala Tyr Gln Glu Ala Met Asp Ile Ser Lys

1 5 10

30

<210> 89

<211> 11
<212> PRT
<213> Homo sapiens

5 <400> 89

Ser Ala Tyr Gln Glu Ala Ile Asp Ile Ser Lys
1 5 10

10

<210> 90
<211> 8
<212> PRT
<213> Homo sapiens

15

<400> 90

Asn Leu Leu Ser Val Ala Tyr Lys
1 5

20

<210> 91
<211> 8
<212> PRT
<213> Homo sapiens

25

<400> 91

Asn Leu Leu Ser Ala Ala Tyr Lys
1 5

30

<210> 92
<211> 11

<212> PRT

<213> Homo sapiens

<400> 92

5

Leu Ala Tyr Gln Glu Ala Met Asp Ile Ser Lys

1 5 10

10

<210> 93

<211> 11

<212> PRT

<213> Homo sapiens

15

<400> 93

Ser Ala Tyr Gln Glu Ala Ile Asp Ile Ser Lys

1 5 10

20

<210> 94

<211> 9

<212> PRT

<213> Homo sapiens

25

<400> 94

Glu Met Pro Pro Thr Asn Pro Ile Arg

1 5

30

<210> 95

<211> 9

<212> PRT

<213> Homo sapiens

<400> 95

5 Glu Met Pro Pro Ser Asn Pro Ile Arg

1 5

<210> 96

10

<211> 9

<212> PRT

<213> Homo sapiens

<400> 96

15

Glu Met Pro Pro Thr Asn Thr Ile Arg

1 5

20

<210> 97

<211> 11

<212> PRT

<213> Homo sapiens

25

<400> 97

Gly Glu Asp Leu Glu Arg Pro Leu Glu Leu Arg

1 5 10

30

<210> 98

<211> 11

<212> PRT

<213> Homo sapiens

<400> 98

5 Gly Glu Asp Leu Glu Ser Pro Leu Glu Leu Arg
1 5 10

<210> 99

<211> 13

10 <212> PRT

<213> Homo sapiens

<400> 99

15 Val Leu Asp Val Asn Asp Asn Phe Pro Thr Leu Glu Lys
1 5 10

<210> 100

20 <211> 13

<212> PRT

<213> Homo sapiens

<400> 100

25 Val Leu Asp Val Asn Asp Asn Phe Pro Ala Leu Glu Lys
1 5 10

30 <210> 101

<211> 21

<212> PRT

<213> Homo sapiens

<400> 101

Asn Gln Ala Asp Phe His Tyr Ser Val Ala Ser Gln Phe Gln Met His

1 5 10 15

5

Pro Thr Pro Val Arg

20

10

<210> 102

<211> 20

<212> PRT

<213> Homo sapiens

15

<400> 102

Gln Ala Asp Phe His Tyr Ser Val Ala Ser Gln Phe Gln Met Asn Pro

1 5 10 15

20

Thr Pro Val Arg

20

25

<210> 103

<211> 27

<212> PRT

<213> Homo sapiens

30

<400> 103

Gly Ser Ser Leu Leu Asn Tyr Val Leu Gly Thr Tyr Thr Ala Ile Asp

1 5 10 15

Leu Asp Thr Gly Asn Pro Ala Thr Asp Val Arg

20 25

5

<210> 104

<211> 26

<212> PRT

10

<213> Homo sapiens

<400> 104

Ser Ser Leu Leu Asn Tyr Val Leu Gly Thr Tyr Thr Ala Ile Asp Leu

1 5 10 15

15

Asp Thr Gly Asn Pro Ala Thr Asp Val Arg

20 25

20

<210> 105

<211> 8

<212> PRT

25

<213> Homo sapiens

<400> 105

Ser Ser Thr Met Gly Thr Leu Arg

1 5

30

<210> 106

<211> 8

<212> PRT

<213> Homo sapiens

<400> 106

5

Ser Ser Thr Met Gly Ala Leu Arg

1 5

10

<210> 107

<211> 15

<212> PRT

<213> Homo sapiens

15

<400> 107

Ile Leu Gly Ala Asp Thr Ser Val Asp Leu Glu Glu Thr Gly Arg

1 5 10 15

20

<210> 108

<211> 15

<212> PRT

<213> Homo sapiens

25

<400> 108

Ile Leu Gly Ala Asp Thr Ser Val Asp Ile Glu Glu Thr Gly Arg

1 5 10 15

30

<210> 109

<211> 10

<212> PRT

<213> Homo sapiens

<400> 109

5 Ala Val Asp Ser Leu Val Pro Ile Gly Arg

1 5 10

<210> 110

10

<211> 10

<212> PRT

<213> Homo sapiens

<400> 110

15

Ala Val Asp Ser Phe Val Pro Ile Gly Arg

1 5 10

20

<210> 111

<211> 12

<212> PRT

<213> Homo sapiens

25

<400> 111

Thr Ser Ile Ala Ile Asp Thr Ile Ile Asn Gln Lys

1 5 10

30

<210> 112

<211> 12

<212> PRT

<213> Homo sapiens

<400> 112

Thr Ser Ile Ala Val Asp Thr Ile Ile Asn Gln Lys

5 1 5 10

<210> 113

<211> 22

10 <212> PRT

<213> Homo sapiens

<400> 113

15 Glu Val Ala Ala Phe Ala Gln Phe Gly Ser Asp Leu Asp Ala Ala Thr

1 5 10 15

Gln Gln Leu Leu Ser Arg

20 20

<210> 114

<211> 7

25 <212> PRT

<213> Homo sapiens

<400> 114

30 Glu Val Ala Ala Phe Ala Gln

1 5

<210> 115

<211> 26
<212> PRT
<213> Homo sapiens

5 <400> 115

Gln Gly Gln Tyr Ser Pro Met Ala Ile Glu Glu Gln Val Ala Val Ile
1 5 10 15

10

Tyr Ala Gly Val Arg Gly Tyr Leu Asp Lys
20 25

15

<210> 116
<211> 9
<212> PRT
<213> Homo sapiens

20

<400> 116

Gln Gly Gln Tyr Ser Pro Met Ala Ile
1 5

25

<210> 117
<211> 10
<212> PRT
<213> Homo sapiens

30

<400> 117

Asp Ala Leu Asn Ile Glu Thr Ala Ile Lys
1 5 10

<210> 118

<211> 10

5

<212> PRT

<213> Homo sapiens

<400> 118

10

Asp Ala Leu Asn Ile Lys Thr Ala Ile Lys

1 5 10

<210> 119

15

<211> 16

<212> PRT

<213> Homo sapiens

<400> 119

20

Ser Ala Leu Ser Gly His Leu Glu Thr Val Ile Leu Gly Leu Leu Lys

1 5 10 15

25

<210> 120

<211> 16

<212> PRT

<213> Homo sapiens

30

<400> 120

Ser Ala Leu Ser Gly His Leu Glu Thr Leu Ile Leu Gly Leu Leu Lys

1 5 10 15

<210> 121

<211> 17

<212> PRT

5 <213> Homo sapiens

<400> 121

Thr Asp Leu Glu Lys Asp Ile Ile Ser Asp Thr Ser Gly Asp Phe Arg

10 1 5 10 15

Lys

15

<210> 122

<211> 11

<212> PRT

20 <213> Homo sapiens

<400> 122

Asp Ile Ile Ser Gly Thr Ser Gly Asp Phe Arg

25 1 5 10

<210> 123

<211> 14

<212> PRT

30 <213> Homo sapiens

<400> 123

Glu Leu Ser Leu Gly Ile Phe Gly Pro Met Pro Asn Leu Arg

1 5 10

5

<210> 124

<211> 14

<212> PRT

<213> Homo sapiens

10

<400> 124

Glu Leu Ser Pro Gly Ile Phe Gly Pro Met Pro Asn Leu Arg

1 5 10

15

<210> 125

<211> 7

<212> PRT

<213> Homo sapiens

20

<400> 125

Asn Thr Asn Ile Ala Gln Lys

1 5

25

<210> 126

<211> 7

<212> PRT

<213> Homo sapiens

30

<400> 126

Asn Thr Asn Phe Ala Gln Lys

1 5

<210> 127

5

<211> 7

<212> PRT

<213> Homo sapiens

<400> 127

10

Val Gln Tyr Asp Leu Gln Lys

1 5

15

<210> 128

<211> 7

<212> PRT

<213> Homo sapiens

20

<400> 128

Val Gln Cys Asp Leu Gln Lys

1 5

25

<210> 129

<211> 11

<212> PRT

<213> Homo sapiens

30

<400> 129

Pro Cys Val Glu Asn Glu Phe Val Ala Leu Lys

1 5 10

<210> 130

<211> 11

5

<212> PRT

<213> Homo sapiens

<400> 130

10

Pro Cys Val Gln Asn Glu Phe Val Ala Leu Lys

1 5 10

<210> 131

15

<211> 21

<212> PRT

<213> Homo sapiens

<400> 131

20

Gly Ala Phe Leu Tyr Glu Pro Cys Gly Val Ser Thr Pro Val Leu Ser

1 5 10 15

25

Thr Gly Val Leu Arg

20

<210> 132

30

<211> 21

<212> PRT

<213> Homo sapiens

<400> 132

Gly Ala Phe Leu Tyr Asp Pro Cys Gly Val Ser Thr Pro Val Leu Ser
1 5 10 15

5

Thr Gly Val Leu Arg
20

10

<210> 133
<211> 21
<212> PRT
<213> Homo sapiens

15

<400> 133

Gly Ala Phe Leu Tyr Asp Pro Cys Gly Val Ser Met Pro Val Leu Ser
1 5 10 15

20

Thr Gly Val Leu Arg
20

25

<210> 134
<211> 11
<212> PRT
<213> Homo sapiens

30

<400> 134

Ala Asp Leu Glu Ala Gln Val Glu Ser Leu Lys
1 5 10

<210> 135
<211> 11
<212> PRT
<213> Homo sapiens

5

<400> 135

Ala Asp Leu Glu Ala Gln Val Glu Tyr Leu Lys

10

1 5 10

<210> 136
<211> 22
<212> PRT
<213> Homo sapiens

15

<400> 136

Leu Pro Cys Asn Pro Cys Ser Thr Pro Ser Cys Thr Thr Cys Val Pro

20

1 5 10 15

Ser Pro Cys Val Thr Arg

25

20

<210> 137
<211> 22
<212> PRT
<213> Homo sapiens

30

<400> 137

Leu Pro Cys Asn Pro Cys Ser Thr Pro Ser Cys Thr Thr Cys Val Pro

1 5 10 15

5 Ser Pro Cys Val Pro Arg

20

<210> 138

10 <211> 28

<212> PRT

<213> Homo sapiens

<400> 138

15

Leu Pro Cys Asn Pro Cys Ser Thr Pro Ser Cys Thr Thr Cys Val Pro

1 5 10 15

20 Ser Pro Cys Val Thr Cys Thr Val Cys Val Pro Arg

20 25

<210> 139

25 <211> 191

<212> PRT

<213> Homo sapiens

<400> 139

30

Met Gly Thr Trp Ile Leu Phe Ala Cys Leu Leu Gly Ala Ala Pro Ala

1 5 10 15

Met Pro Leu Pro Pro His Pro Gly His Pro Gly Tyr Ile Asn Phe Ser

20 25 30

5 Tyr Glu Val Leu Thr Pro Leu Lys Trp Tyr Gln Ser Ile Arg Pro Pro

35 40 45

10 Tyr Pro Ser Tyr Gly Tyr Glu Pro Met Gly Gly Trp Leu His His Gln

50 55 60

15 Ile Ile Pro Val Leu Ser Gln Gln His Pro Pro Thr His Thr Leu Gln

65 70 75 80

Pro His His His Ile Pro Val Val Pro Ala Gln Gln Pro Val Ile Pro

85 90 95

20 Gln Gln Pro Met Met Pro Val Pro Gly Gln His Ser Met Thr Pro Ile

100 105 110

25 Gln His His Gln Pro Asn Leu Pro Pro Pro Ala Gln Gln Pro Tyr Gln

115 120 125

30 Pro Gln Pro Val Gln Pro Gln Pro His Gln Pro Met Gln Pro Gln Pro

130 135 140

Pro Val His Pro Met Gln Pro Leu Pro Pro Gln Pro Pro Leu Pro Pro

145 150 155 160

Met Pro Pro Met Gln Pro Leu Pro Pro Met Leu Pro Asp Leu Thr Leu

165 170 175

5

Glu Ala Trp Pro Ser Thr Asp Lys Thr Lys Arg Glu Glu Val Asp

180 185 190

10

<210> 140

<211> 206

<212> PRT

<213> Homo sapiens

15

<400> 140

Met Gly Thr Trp Ile Leu Phe Ala Cys Leu Val Gly Ala Ala Pro Ala

1 5 10 15

20

Met Pro Leu Pro Pro His Pro Gly His Pro Gly Tyr Ile Asn Phe Ser

20 25 30

25

Tyr Glu Asn Ser His Ser Gln Ala Ile Asn Val Asp Arg Ile Ala Leu

35 40 45

30

Val Leu Thr Pro Leu Lys Trp Tyr Gln Ser Met Ile Arg Pro Pro Tyr

50 55 60

Ser Ser Tyr Gly Tyr Glu Pro Met Gly Gly Trp Leu His His Gln Ile

90

65 70 75 80

Ile Pro Val Val Ser Gln Gln His Pro Leu Thr His Thr Leu Gln Ser

5

85 90 95

His His His Ile Pro Val Val Pro Ala Gln Gln Pro Arg Val Arg Gln

10

100 105 110

Gln Ala Leu Met Pro Val Pro Gly Gln Gln Ser Met Thr Pro Thr Gln

15

115 120 125

His His Gln Pro Asn Leu Pro Leu Pro Ala Gln Gln Pro Phe Gln Pro

130 135 140

20

Gln Pro Val Gln Pro Gln Pro His Gln Pro Met Gln Pro Gln Pro Pro

145 150 155 160

Val Gln Pro Met Gln Pro Leu Leu Pro Gln Pro Pro Leu Pro Pro Met

25

165 170 175

Pro Pro Leu Arg Pro Leu Pro Pro Ile Leu Pro Asp Leu His Leu Glu

180 185 190

30

Ala Trp Pro Ala Thr Asp Lys Thr Lys Gln Glu Glu Val Asp

195 200 205